[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 110
1. Leoncini G, Maio V, Puccioni M, Franchi A, De Giorgi V, Ucci F, Santucci M, Massi D: Orbital solitary fibrous tumor: a case report and review of the literature. Pathol Oncol Res; 2008 Jun;14(2):213-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Orbital solitary fibrous tumor: a case report and review of the literature.
  • Solitary fibrous tumor (SFT) is a rare spindle cell neoplasm typically arising in the pleura and involving the orbit as its most common extra-pleural location.
  • The tumor had a benign clinical course, with radical surgical excision followed by regression of the clinical symptoms.
  • We review the clinical, histopathological, and immunohistochemical features of the orbital SFT described so far, with particular emphasis on differential diagnosis with other spindle cell orbital neoplasms.
  • [MeSH-major] Orbital Neoplasms / diagnosis. Orbital Neoplasms / surgery. Solitary Fibrous Tumors / diagnosis. Solitary Fibrous Tumors / surgery
  • [MeSH-minor] Diagnosis, Differential. Exophthalmos / etiology. Female. Humans. Immunohistochemistry. Middle Aged. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eye (Lond). 2001 Feb;15(Pt 1):102-4 [11318269.001]
  • [Cites] Am J Surg Pathol. 1989 Aug;13(8):640-58 [2665534.001]
  • [Cites] Am J Clin Pathol. 1996 Sep;106(3):325-31 [8816589.001]
  • [Cites] Am J Surg Pathol. 1989 Jul;13(7):547-57 [2735490.001]
  • [Cites] Hum Pathol. 1999 Dec;30(12):1464-73 [10667425.001]
  • [Cites] Am J Surg Pathol. 1991 Feb;15(2):126-30 [1989459.001]
  • [Cites] Neurosurgery. 2001 Nov;49(5):1241-5 [11846919.001]
  • [Cites] Am J Dermatopathol. 1999 Jun;21(3):213-9 [10380040.001]
  • [Cites] Semin Diagn Pathol. 1992 May;9(2):169-80 [1609159.001]
  • [Cites] Am J Surg Pathol. 1998 Dec;22(12 ):1501-11 [9850176.001]
  • [Cites] Mod Pathol. 1999 May;12 (5):463-71 [10349983.001]
  • [Cites] Mod Pathol. 1997 Oct;10(10):1028-37 [9346183.001]
  • [Cites] Histopathology. 1997 Dec;31(6):568-76 [9447390.001]
  • [Cites] Mod Pathol. 1996 Dec;9(12):1170-4 [8972477.001]
  • [Cites] Br J Urol. 1994 Dec;74(6):798-9 [7827857.001]
  • [Cites] Am J Surg Pathol. 1991 Sep;15(9):842-8 [1719831.001]
  • [Cites] Histopathology. 1997 May;30(5):451-6 [9181366.001]
  • [Cites] Cancer. 1989 Sep 1;64(5):1096-102 [2474368.001]
  • [Cites] Ophthalmology. 1996 Oct;103(10):1613-8 [8874434.001]
  • [Cites] Am J Clin Pathol. 1989 Nov;92(5):561-5 [2479254.001]
  • [Cites] Ophthal Plast Reconstr Surg. 1999 Nov;15(6):450-3 [10588259.001]
  • [Cites] Neuroradiology. 1999 Jan;41(1):52-4 [9987770.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 2002 Jul;240(7):570-4 [12136289.001]
  • (PMID = 18493869.001).
  • [ISSN] 1219-4956
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 26
  •  go-up   go-down


2. Carretta A, Bandiera A, Melloni G, Ciriaco P, Arrigoni G, Rizzo N, Negri G, Zannini P: Solitary fibrous tumors of the pleura: Immunohistochemical analysis and evaluation of prognostic factors after surgical treatment. J Surg Oncol; 2006 Jul 1;94(1):40-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary fibrous tumors of the pleura: Immunohistochemical analysis and evaluation of prognostic factors after surgical treatment.
  • BACKGROUND AND OBJECTIVES: Solitary fibrous tumors of the pleura (SFTP) are rare neoplasms with unusual histological and clinical features.
  • Although surgery is the treatment of choice for SFTP, tumor recurrence may occur after complete resection, even in tumors with benign histological features.
  • Mean tumor size was 10 cm.
  • Histological features were benign in 16 patients and malignant in 2.
  • A higher incidence of tumor recurrence was observed when SFTP originated from the parietal pleura, had malignant histological features and a lower expression of progesterone receptors (P < 0.05).
  • [MeSH-major] Fibroma / pathology. Fibroma / surgery. Neoplasm Recurrence, Local / pathology. Pleural Neoplasms / pathology. Pleural Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • (PMID = 16788942.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Estrogen; 0 / Receptors, Progesterone
  •  go-up   go-down


3. Fatima S, Ahmed Z, Azam M: Benign metastasizing leiomyoma. Indian J Pathol Microbiol; 2010 Oct-Dec;53(4):802-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign metastasizing leiomyoma.
  • Benign metastasizing leiomyoma (BML) is a rare condition, affecting predominantly reproductive-age females with uterine leiomyomata and is most often associated with multiple benign-appearing smooth muscle tumors in lungs.
  • Postoperatively, she developed left-sided pleural effusion.
  • Histopathology of one of the pleura-based nodules revealed a neoplasm composed of interlacing fascicles of spindle cells with uniform nuclei.
  • The tumor cells were positive for alpha-smooth muscle actin and negative for CD34 immunohistochemical stain.
  • [MeSH-major] Leiomyoma / diagnosis. Lung Neoplasms / secondary. Pleural Neoplasms / secondary. Uterine Neoplasms / diagnosis
  • [MeSH-minor] Actins / analysis. Adult. Antigens, CD34 / analysis. Female. Histocytochemistry. Humans. Hysterectomy. Immunohistochemistry. Microscopy. Pleural Effusion / diagnosis. Radiography, Thoracic. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Fibroids.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21045423.001).
  • [ISSN] 0974-5130
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / ACTA2 protein, human; 0 / Actins; 0 / Antigens, CD34
  •  go-up   go-down


Advertisement
4. Shitrit D, Zingerman B, Shitrit AB, Shlomi D, Kramer MR: Diagnostic value of CYFRA 21-1, CEA, CA 19-9, CA 15-3, and CA 125 assays in pleural effusions: analysis of 116 cases and review of the literature. Oncologist; 2005 Aug;10(7):501-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic value of CYFRA 21-1, CEA, CA 19-9, CA 15-3, and CA 125 assays in pleural effusions: analysis of 116 cases and review of the literature.
  • Levels of tumor markers in pleural effusions may help to establish the diagnosis of pleural malignancy, but the precise diagnostic value of each marker remains unclear.
  • The aim of this study was to assess the diagnostic value of five common pleural fluid tumor markers, carcinoembryonic antigen (CEA), cytokeratin fragment (CYFRA) 21-1, cancer antigen (CA) 15-3, CA 19-9, and CA 125, and to review the literature from the past 15 years.
  • Pleural fluid samples were collected prospectively from 116 patients and assayed for CEA, CYFRA 21-1, CA 15-3, CA 19-9, and CA 125 levels.
  • Effusions were classified as benign or malignant on the basis of their definitive pathologic or cytologic diagnoses.
  • The levels of all pleural tumor markers were statistically significantly higher in the malignant group than in the benign group.
  • On univariate analysis, tumor-marker combinations did not result in a greater accuracy than that of CEA alone.
  • Among the nine reports in the literature comparing 11 different tumor markers, CEA, CA 15-3, and CYFRA 21-1 yielded the best results.
  • We conclude that pleural fluid analysis should include CEA for the diagnosis of malignancy.
  • [MeSH-major] Antigens, Neoplasm. CA-125 Antigen. CA-19-9 Antigen. Carcinoembryonic Antigen. Mucin-1. Pleural Effusion / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Keratin-19. Keratins. Male. Middle Aged. Prospective Studies

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16079317.001).
  • [ISSN] 1083-7159
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / CA-125 Antigen; 0 / CA-19-9 Antigen; 0 / Carcinoembryonic Antigen; 0 / Keratin-19; 0 / Mucin-1; 0 / antigen CYFRA21.1; 68238-35-7 / Keratins
  •  go-up   go-down


5. Wang HY, Fan QH, Gong QX, Wang Z: [Clinicopathologic characteristics of hemangiopericytoma/solitary fibrous tumor with giant cells]. Zhonghua Bing Li Xue Za Zhi; 2009 Mar;38(3):169-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathologic characteristics of hemangiopericytoma/solitary fibrous tumor with giant cells].
  • OBJECTIVE: To study the pathological characteristics, diagnosis and differential diagnoses of hemangiopericytoma-solitary fibrous tumor with giant cells.
  • Seven patients underwent tumor excision and were well and without tumor recurrence upon the clinical follow-up.
  • CONCLUSIONS: Hemangiopericytoma-solitary fibrous tumor with giant cells is an intermediate soft tissue tumor.
  • Histologically, the tumor should be distinguished from giant cell fibroblastoma, pleomorphic hyalinzing angiectatic tumor of soft part and angiomatoid fibrous histiocytoma.
  • [MeSH-minor] Adult. Antigens, CD / metabolism. Antigens, CD34 / metabolism. Cell Adhesion Molecules / metabolism. Dermatofibrosarcoma / pathology. Diagnosis, Differential. Female. Follow-Up Studies. Histiocytoma, Benign Fibrous / pathology. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Recurrence, Local. Proto-Oncogene Proteins c-bcl-2 / metabolism. Soft Tissue Neoplasms / pathology. Solitary Fibrous Tumor, Pleural / metabolism. Solitary Fibrous Tumor, Pleural / pathology. Solitary Fibrous Tumor, Pleural / surgery. Young Adult

  • Genetic Alliance. consumer health - Hemangiopericytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19575851.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD34; 0 / CD99 protein, human; 0 / Cell Adhesion Molecules; 0 / Proto-Oncogene Proteins c-bcl-2
  •  go-up   go-down


6. Granville L, Laga AC, Allen TC, Dishop M, Roggli VL, Churg A, Zander DS, Cagle PT: Review and update of uncommon primary pleural tumors: a practical approach to diagnosis. Arch Pathol Lab Med; 2005 Nov;129(11):1428-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Review and update of uncommon primary pleural tumors: a practical approach to diagnosis.
  • OBJECTIVE: We address the current classifications and new changes regarding uncommon primary pleural tumors.
  • Primary pleural tumors are divided according to their behavior and are discussed separately as benign tumors, tumors of low malignant potential, and malignant neoplasms.
  • DATA SOURCES: Current literature concerning primary pleural neoplasms was collected and reviewed.
  • STUDY SELECTION: Studies emphasizing clinical, radiological, or pathologic findings of primary pleural neoplasms were obtained.
  • DATA EXTRACTION: Data deemed helpful to the general surgical pathologist when confronted with an uncommon primary pleural tumor was included in this review.
  • (1) benign, (2) low malignant potential, and (3) malignant.
  • A practical approach to the diagnosis of these neoplasms in surgical pathology specimens is offered.
  • The differential diagnosis, including metastatic pleural neoplasms, is also briefly addressed.
  • CONCLUSIONS: Uncommon primary pleural neoplasms may mimic each other, as well as mimic metastatic cancers to the pleura and diffuse malignant mesothelioma.
  • Correct diagnosis is important because of different prognosis and treatment implications for the various neoplasms.
  • [MeSH-major] Medical Oncology / methods. Mesothelioma / pathology. Neoplasm Metastasis / pathology. Pleural Neoplasms / pathology
  • [MeSH-minor] Biopsy. Diagnosis, Differential. Humans. Pleura / pathology

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16253024.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Review
  • [Publication-country] United States
  • [Number-of-references] 131
  •  go-up   go-down


7. Mahmood S, Martinez de Llano SR: Paget disease of the humerus mimicking metastatic disease in a patient with metastatic malignant mesothelioma on whole body F-18 FDG PET/CT. Clin Nucl Med; 2008 Jul;33(7):510-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PET showed mild FDG uptake in the right chest, corresponding to a lobulated, mass-like right pleural effusion versus thickening involving the entire right pleural space, and some mediastinal involvement, on the accompanying CT scan.
  • The intense FDG uptake in an osseous lesion on FDG-PET in our case reminds us of the variable nature of FDG uptake in Paget disease, the possibility of false-positive findings on FDG-PET in patients with cancer, and the usefulness of the fusion techniques in the evaluation of skeletal lesions, with the potential for discriminating between benign Paget disease and other pathologic bone findings.
  • [MeSH-major] Bone Neoplasms / diagnosis. Bone Neoplasms / radionuclide imaging. Humerus / radionuclide imaging. Lung Neoplasms / diagnosis. Lung Neoplasms / radionuclide imaging. Mesothelioma / diagnosis. Mesothelioma / radionuclide imaging. Neoplasms, Second Primary / diagnosis. Neoplasms, Second Primary / radionuclide imaging. Osteitis Deformans / diagnosis. Osteitis Deformans / radionuclide imaging
  • [MeSH-minor] Aged. Fluorodeoxyglucose F18 / pharmacology. Humans. Male. Neoplasm Metastasis. Positron-Emission Tomography / methods. Radiopharmaceuticals / pharmacology. Tomography, X-Ray Computed / methods


8. Schneider J, Hoffmann H, Dienemann H, Herth FJ, Meister M, Muley T: Diagnostic and prognostic value of soluble mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer. J Thorac Oncol; 2008 Nov;3(11):1317-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic and prognostic value of soluble mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer.
  • INTRODUCTION AND METHODS: We investigated the diagnostic and prognostic value of soluble mesothelin-related proteins (SMRP) in sera from patients with newly diagnosed malignant pleural mesothelioma (MPM) (n = 100), MPM patients at tumor relapse (n = 29), primary lung cancer (n = 139), and benign asbestosis (n = 75) using Mesomark--enzyme-linked immunosorbent assay kit (Fujirebio Diagnostics, Malvern, PA).
  • RESULTS: SMRP concentrations were significantly higher in MPM compared with benign asbestosis (p < 0.001) or lung cancer (p < 0.001).
  • CONCLUSION: In conclusion, SMRP add limited information to the diagnosis of MPM.
  • [MeSH-major] Asbestosis / diagnosis. Biomarkers, Tumor / blood. Lung Neoplasms / diagnosis. Membrane Glycoproteins / blood. Mesothelioma / diagnosis. Pleural Effusion, Malignant / diagnosis
  • [MeSH-minor] Antigens, Neoplasm / blood. Female. GPI-Linked Proteins. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Prospective Studies. Survival Rate


9. Moon H, Park SJ, Lee HB, Kim SR, Choe YH, Chung MJ, Jin GY, Lee YC: Pulmonary benign metastasizing leiomyoma in a postmenopausal woman. Am J Med Sci; 2009 Jul;338(1):72-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary benign metastasizing leiomyoma in a postmenopausal woman.
  • Pulmonary benign metastasizing leiomyoma (BML) is a rare disease occurring predominantly in women of reproductive age and usually develops several years after the resection of a uterine leiomyoma.
  • Contrast-enhanced computed tomography showed a multiloculated pleural effusion on the right side and multiple small nodules in the left lung.
  • [MeSH-minor] Female. Humans. Middle Aged. Neoplasm Metastasis. Postmenopause

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Fibroids.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19506459.001).
  • [ISSN] 0002-9629
  • [Journal-full-title] The American journal of the medical sciences
  • [ISO-abbreviation] Am. J. Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Li CS, Cheng BC, Ge W, Gao JF: Clinical value of CYFRA21-1, NSE, CA15-3, CA19-9 and CA125 assay in the elderly patients with pleural effusions. Int J Clin Pract; 2007 Mar;61(3):444-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical value of CYFRA21-1, NSE, CA15-3, CA19-9 and CA125 assay in the elderly patients with pleural effusions.
  • The aim of this study was to evaluate the individual and combined diagnostic value of five tumour markers in the elderly patients with pleural effusions.
  • Serum and pleural fluid levels of cytokeratin fragment 19 (CYFRA21-1), neuron-specific enolase (NSE), carbohydrate antigen 15-3 (CA15-3), carbohydrate antigen 19-9 (CA19-9) and carbohydrate antigen 125 (CA125) were assayed in 32 elderly patients with malignant pleural effusions resulting from advanced lung cancer and in 30 elderly patients with benign pleural effusions by ELISA.
  • Serum levels of CYFRA21-1, NSE, CA15-3, CA19-9 and CA125 in patients with malignant pleural effusions were 12.84 +/- 6.48 microg/l, 22.07 +/- 11.25 microg/l, 65.74 +/- 30.26 kU/l, 56.32 +/- 25.6 kU/l and 71.86 +/- 31.45 kU/l, respectively, and were significantly higher than those in patients with benign pleural effusions (p < 0.01).
  • Pleural fluid levels of CYFRA21-1, CA15-3, CA19-9 and CA125 except NSE in patients with malignant pleural effusions were 18.64 +/- 8.15 microg/l, 59.31 +/- 27.35 kU/l, 48.24 +/- 21.56 kU/l and 62.16 +/- 27.79 kU/l, respectively, and were significantly higher than those in patients with benign pleural effusions (p < 0.01).
  • The parallel combined testing of five tumour markers in serum increased the diagnostic sensitivity to 90.6%, and serial combined testing increased the diagnostic specificity to 93.3%.
  • The sensitivity (%) and specificity (%) of these tumour markers in pleural fluid were as follows: CYFRA21-1, 84.4/90; CA15-3, 62.5/73.3; CA19-9, 37.5/66.7; CA125, 56.3/70; for differentiating malignant effusions from benign effusions.
  • Serum and pleural fluid levels of the five tumour markers shows certain values in the diagnosis and differentiate diagnosis for malignant pleural effusions in the elderly patients from benign.
  • The combined assay of five tumour markers in serum and the CYFRA21-1 combined with CA15-3 in pleural fluid were helpful and can increase the sensitivity and specificity in diagnosing malignant pleural effusions.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Lung Neoplasms / diagnosis. Pleural Effusion / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Antigens, Neoplasm / metabolism. CA-125 Antigen / metabolism. CA-19-9 Antigen / metabolism. Diagnosis, Differential. Female. Humans. Keratin-19. Keratins / metabolism. Male. Middle Aged. Mucin-1 / metabolism. Phosphopyruvate Hydratase / metabolism. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17313612.001).
  • [ISSN] 1368-5031
  • [Journal-full-title] International journal of clinical practice
  • [ISO-abbreviation] Int. J. Clin. Pract.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / CA-19-9 Antigen; 0 / Keratin-19; 0 / Mucin-1; 0 / antigen CYFRA21.1; 68238-35-7 / Keratins; EC 4.2.1.11 / Phosphopyruvate Hydratase
  •  go-up   go-down


11. Davidson B, Elstrand MB, McMaster MT, Berner A, Kurman RJ, Risberg B, Trope CG, Shih IeM: HLA-G expression in effusions is a possible marker of tumor susceptibility to chemotherapy in ovarian carcinoma. Gynecol Oncol; 2005 Jan;96(1):42-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HLA-G expression in effusions is a possible marker of tumor susceptibility to chemotherapy in ovarian carcinoma.
  • OBJECTIVE: We recently showed that the levels of secreted human leukocyte antigen-G (HLA-G), a nonclassical MHC class I antigen, are significantly elevated in malignant effusions in ovarian carcinoma compared to benign ones.
  • HLA-G expression in tumor cells was significantly lower in effusions obtained during or following chemotherapy (P = 0.038).
  • The presence of HLA-G-positive tumor cells in effusions obtained prior to the institution of chemotherapy correlated with better overall survival (P = 0.042).
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. HLA Antigens / biosynthesis. Histocompatibility Antigens Class I / biosynthesis. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / immunology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal / chemistry. Ascitic Fluid / immunology. Female. HLA-G Antigens. Humans. Immunohistochemistry. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Pleural Effusion / immunology. Prognosis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15589578.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Biomarkers, Tumor; 0 / HLA Antigens; 0 / HLA-G Antigens; 0 / Histocompatibility Antigens Class I
  •  go-up   go-down


12. Loizzi V, Cormio G, Resta L, Fattizzi N, Vicino M, Selvaggi L: Pseudo-Meigs syndrome and elevated CA125 associated with struma ovarii. Gynecol Oncol; 2005 Apr;97(1):282-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Struma ovarii is a rare form of ovarian neoplasm composed entirely and predominantly of thyroid tissue.
  • CASE: We report an unusual presentation of a postmenopausal woman with benign struma ovarii associated with pseudo-Meigs syndrome, hypertiroidism, and elevated CA125 serum level, and a large complex right pelvic mass thereby mimicking an ovarian cancer.
  • This rare condition should be considered in the differential diagnosis in patients with ascites and pleural effusions but with negative cytology.
  • [MeSH-major] CA-125 Antigen / blood. Carcinoid Tumor / blood. Meigs Syndrome / blood. Ovarian Neoplasms / blood. Struma Ovarii / blood
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans. Hyperthyroidism / blood

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15790478.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CA-125 Antigen
  •  go-up   go-down


13. Zhang Y, Gomez-Fernandez CR, Jorda M, Ganjei-Azar P: Fine-needle aspiration (FNA) and pleural fluid cytology diagnosis of benign metastasizing pleomorphic adenoma of the parotid gland in the lung: a case report and review of literature. Diagn Cytopathol; 2009 Nov;37(11):828-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine-needle aspiration (FNA) and pleural fluid cytology diagnosis of benign metastasizing pleomorphic adenoma of the parotid gland in the lung: a case report and review of literature.
  • Lesions that contain abundant benign myoepithelial cells, including pleomorphic adenomas of salivary gland origin, may present a diagnostic challenge in fine-needle aspiration (FNA) specimens.
  • Benign metastasizing pleomorphic adenoma is a rare neoplasm, in which the benign appearing pleomorphic adenoma, without any histological evidence of malignancy, metastasizes to distant sites including lung.
  • In the absence of clinical history of a pre-existing myoepithelial neoplasm, the presence of myoepithelial cells in the lung or any other organs besides salivary glands may create diagnostic difficulty.
  • Here we present the cytologic findings of such a metastatic tumor found in the lung FNA and pleural fluid specimens from a 64-year-old woman, with a history of local recurrent salivary gland pleomorphic adenomas, who presented with multiple bilateral pulmonary nodules and pleural effusion.
  • The diagnosis of benign metastasizing pleomorphic adenoma was made based on clinical information and cytomorphology, and confirmed by immunocytochemistry.
  • [MeSH-major] Adenoma, Pleomorphic / pathology. Biopsy, Fine-Needle. Lung Neoplasms / secondary. Parotid Neoplasms / pathology. Pleural Effusion, Malignant / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19582818.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 15
  •  go-up   go-down


14. Salahudeen HM, Hoey ET, Robertson RJ, Darby MJ: CT appearances of pleural tumours. Clin Radiol; 2009 Sep;64(9):918-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CT appearances of pleural tumours.
  • Computed tomography (CT) is the imaging technique of choice for characterizing pleural masses with respect to their location, composition, and extent.
  • A spectrum of tumours can affect the pleura of which metastatic adenocarcinoma is the commonest cause of malignant pleural disease, while malignant mesothelioma is the most common primary pleural tumour.
  • Certain CT features help differentiate benign from malignant processes.
  • This pictorial review highlights the salient CT appearances of a range of tumours that may affect the pleura.
  • [MeSH-major] Pleural Neoplasms / radiography. Tomography, X-Ray Computed
  • [MeSH-minor] Adenocarcinoma / radiography. Adenocarcinoma / secondary. Aged. Asbestos / adverse effects. Female. Fibroma / radiography. Humans. Lipoma / radiography. Lymphoma / radiography. Male. Mesothelioma / pathology. Mesothelioma / radiography. Neoplasm Staging / methods. Occupational Exposure / adverse effects. Pleura / anatomy & histology. Pleura / radiography. Sarcoma / radiography

  • MedlinePlus Health Information. consumer health - CT Scans.
  • Hazardous Substances Data Bank. ASBESTOS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19664483.001).
  • [ISSN] 1365-229X
  • [Journal-full-title] Clinical radiology
  • [ISO-abbreviation] Clin Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 1332-21-4 / Asbestos
  • [Number-of-references] 95
  •  go-up   go-down


15. Wagner IC, Guimarães MJ, da Silva LK, de Melo FM, Muniz MT: Evaluation of serum and pleural levels of the tumor markers CEA, CYFRA21-1 and CA 15-3 in patients with pleural effusion. J Bras Pneumol; 2007 Mar-Apr;33(2):185-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of serum and pleural levels of the tumor markers CEA, CYFRA21-1 and CA 15-3 in patients with pleural effusion.
  • OBJECTIVE: To determine the levels of the tumor markers carcinoembryonic antigen (CEA), cytokeratin 19 fragment (CYFRA21-1) and carbohydrate antigen 15-3 (CA 15-3) in the blood and pleural fluid of patients with benign or malignant pleural effusion, evaluating the sensitivity of each marker in these fluids.
  • METHODS: We prospectively evaluated 85 patients with pleural effusion.
  • The study of the pleural fluid observed the criteria established in the literature.
  • RESULTS: Of the 85 cases, 36 (42.4%) were malignant, 30 (35.3%) were benign, and the results were inconclusive in 19 (22.3%).
  • In the malignant cases, the CEA and CYFRA21-1 levels were higher in the pleural fluid than in the blood, which was not observed for CA 15-3.
  • In the benign cases, the CYFRA21-1 levels were higher in the pleural fluid than in the blood, whereas the opposite was found for CEA and CA 15-3.
  • There were significant differences between malignant and benign cases for all markers, in pleural fluid and blood.
  • In the pleural fluid, the sensitivity of CEA, CYFRA21-1 and CA 15-3 was 69.4, 69.4 and 66.7%, respectively, and the combined sensitivity was 80.6%.
  • CONCLUSION: The results suggest that these markers might be useful in the differentiation between malignant and benign pleural effusion.
  • [MeSH-major] Antigens, Neoplasm / analysis. Biomarkers, Tumor / analysis. Carcinoembryonic Antigen / analysis. Keratins / analysis. Mucin-1 / analysis. Pleural Effusion, Malignant / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Electrochemistry. Epidemiologic Methods. Female. Heart Failure / diagnosis. Humans. Keratin-19. Liver Diseases / diagnosis. Luminescent Measurements. Male. Middle Aged. Tuberculosis, Pulmonary / diagnosis

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17724538.001).
  • [ISSN] 1806-3756
  • [Journal-full-title] Jornal brasileiro de pneumologia : publicaça̋o oficial da Sociedade Brasileira de Pneumologia e Tisilogia
  • [ISO-abbreviation] J Bras Pneumol
  • [Language] eng; por
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 0 / Keratin-19; 0 / Mucin-1; 0 / antigen CYFRA21.1; 68238-35-7 / Keratins
  •  go-up   go-down


16. Yannopoulos P, Theodoridis P, Manes K: Esophagectomy without thoracotomy: 25 years of experience over 750 patients. Langenbecks Arch Surg; 2009 Jul;394(4):611-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: This is a retrospective analysis of all THE operations performed between January 1981 until May 2007 in 750 patients: 60 patients (8%) had benign lesions, while 690 (92%) had malignant ones (5.2% of malignancies were located in the upper esophagus, 7.4% in the middle esophagus, 19% in the lower esophagus, and 68.4% at the cardioesophageal junction).
  • Major complications included atelectasis or pneumonia (4.8%), pleural effusion (22.7%), myocardial infarction (0.5%), recurrent laryngeal nerve paralysis (1.33%), and three tracheal lacerations (0.4%).

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Surg. 2001 Feb;25(2):196-203 [11338022.001]
  • [Cites] Ann Surg. 2007 Sep;246(3):363-72; discussion 372-4 [17717440.001]
  • [Cites] Ann Thorac Surg. 2001 Dec;72(6):1918-24; discussion 1924-5 [11789772.001]
  • [Cites] Am J Surg. 2002 Feb;183(2):162-7 [11918882.001]
  • [Cites] Semin Thorac Cardiovasc Surg. 2003 Apr;15(2):197-209 [12838490.001]
  • [Cites] Dis Esophagus. 2003;16(3):243-5 [14641318.001]
  • [Cites] Arch Surg. 2004 Jun;139(6):627-31; discussion 631-3 [15197089.001]
  • [Cites] Ann Thorac Surg. 2004 Oct;78(4):1170-6; discussion 1170-6 [15464465.001]
  • [Cites] Br J Surg. 1975 Aug;62(8):601-4 [1174797.001]
  • [Cites] J Thorac Cardiovasc Surg. 1978 Nov;76(5):643-54 [703369.001]
  • [Cites] Eur J Cardiothorac Surg. 1989;3(5):419-23; discussion 424 [2635923.001]
  • [Cites] Aust N Z J Surg. 1991 May;61(5):366-9 [2025191.001]
  • [Cites] Ann Surg. 1994 Sep;220(3):364-72; discussion 372-3 [8092902.001]
  • [Cites] J Surg Oncol. 1994 Nov;57(3):157-63 [7967604.001]
  • [Cites] Chest Surg Clin N Am. 1997 Aug;7(3):601-10; discussion 611-2 [9246405.001]
  • [Cites] J Thorac Cardiovasc Surg. 1997 Dec;114(6):948-55; discussion 955-6 [9434690.001]
  • [Cites] Surgery. 1999 Feb;125(2):142-7 [10026746.001]
  • [Cites] Ann Surg. 1999 Sep;230(3):392-400; discussion 400-3 [10493486.001]
  • [Cites] Surg Clin North Am. 2005 Jun;85(3):593-610 [15927654.001]
  • [Cites] Ann Thorac Surg. 2001 Jul;72(1):306-13 [11465217.001]
  • (PMID = 19350267.001).
  • [ISSN] 1435-2451
  • [Journal-full-title] Langenbeck's archives of surgery
  • [ISO-abbreviation] Langenbecks Arch Surg
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC2687514
  •  go-up   go-down


17. Passebosc-Faure K, Li G, Lambert C, Cottier M, Gentil-Perret A, Fournel P, Pérol M, Genin C: Evaluation of a panel of molecular markers for the diagnosis of malignant serous effusions. Clin Cancer Res; 2005 Oct 1;11(19 Pt 1):6862-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of a panel of molecular markers for the diagnosis of malignant serous effusions.
  • EXPERIMENTAL DESIGN: One hundred fourteen serous effusions from 71 patients with tumors and 43 patients with benign diseases were subjected to RT-PCR for expression of carcinoembryonic antigen (CEA), epithelial cell adhesion molecule (Ep-CAM), E-cadherin, mammaglobin, mucin 1 (MUC1) isoforms MUC1/REP, MUC1/Y, and MUC1/Z, calretinin, and Wilms' tumor 1 susceptibility gene.
  • CONCLUSIONS: A combination of cytology and RT-PCR analysis of CEA and Ep-CAM significantly improved the detection sensitivity of tumor cells in serous effusions.
  • RT-PCR analysis of CEA, Ep-CAM, and mammaglobin in serous effusions could be a beneficial adjunct to cytology for the diagnosis of malignancy.
  • [MeSH-major] Biomarkers, Tumor. Genetic Predisposition to Disease. Pleural Effusion, Malignant / genetics. Pleural Effusion, Malignant / metabolism
  • [MeSH-minor] Aged. Antigens / biosynthesis. Antigens, Neoplasm / biosynthesis. Ascites / metabolism. Cadherins / biosynthesis. Calbindin 2. Carcinoembryonic Antigen / biosynthesis. Carcinoma / metabolism. Cell Adhesion Molecules / biosynthesis. Cell Line, Tumor. DNA Primers / chemistry. Female. Genes, Wilms Tumor. Glycoproteins / biosynthesis. Humans. Male. Mammaglobin A. Middle Aged. Mucin-1. Mucins / biosynthesis. Neoplasm Proteins / biosynthesis. Oligonucleotides, Antisense / chemistry. Pleural Effusion. RNA / metabolism. Reverse Transcriptase Polymerase Chain Reaction. S100 Calcium Binding Protein G / biosynthesis. Sensitivity and Specificity. Uteroglobin / biosynthesis. WT1 Proteins / biosynthesis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16203775.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / CALB2 protein, human; 0 / Cadherins; 0 / Calbindin 2; 0 / Carcinoembryonic Antigen; 0 / Cell Adhesion Molecules; 0 / DNA Primers; 0 / EPCAM protein, human; 0 / Glycoproteins; 0 / MUC1 protein, human; 0 / Mammaglobin A; 0 / Mucin-1; 0 / Mucins; 0 / Neoplasm Proteins; 0 / Oligonucleotides, Antisense; 0 / S100 Calcium Binding Protein G; 0 / SCGB2A2 protein, human; 0 / WT1 Proteins; 63231-63-0 / RNA; 9060-09-7 / Uteroglobin
  •  go-up   go-down


18. Patel T, Bansal R, Trivedi P, Modi L, Shah MJ: Subcutaneous metastases of sarcomatoid mesothelioma with its differential diagnosis on fine needle aspiration--a case report. Indian J Pathol Microbiol; 2005 Oct;48(4):482-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subcutaneous metastases of sarcomatoid mesothelioma with its differential diagnosis on fine needle aspiration--a case report.
  • Metastasis of mesothelioma of the pleura, to the skin and subcutis is an extremely rare occurrence.
  • A 25 year old woman, who had undergone chemotherapy, partial excision of tumor followed by radiotherapy of sarcomatoid mesothelioma of the pleura, presented three months later with painless widespread subcutaneous nodules.
  • It is essential to differentiate neoplasm metastatic to the skin and subcutis from primary and benign lesions of the same region.
  • FNAC is accurate and efficient, in conjugation with clinical history, and it also prevents surgical biopsy in the diagnosis of metastatic subcutaneous lesion.
  • [MeSH-major] Mesothelioma / diagnosis. Soft Tissue Neoplasms / diagnosis
  • [MeSH-minor] Adult. Biopsy, Fine-Needle. Diagnosis, Differential. Female. Humans. Pleural Neoplasms. Skin Neoplasms / diagnosis. Skin Neoplasms / secondary. Subcutaneous Tissue

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16366102.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


19. Sung SH, Chang JW, Kim J, Lee KS, Han J, Park SI: Solitary fibrous tumors of the pleura: surgical outcome and clinical course. Ann Thorac Surg; 2005 Jan;79(1):303-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary fibrous tumors of the pleura: surgical outcome and clinical course.
  • BACKGROUND: The aim of this study was to define more precisely the surgical outcome and clinical course of solitary fibrous tumors of the pleura.
  • METHODS: We conducted a retrospective review of the clinical records of patients who had undergone surgical resection for benign and malignant solitary fibrous tumors of the pleura during a 10-year period (1993 to 2003).
  • Thirty-six patients (57.1%) were symptomatic at the time of diagnosis.
  • Forty-four cases (69.8%) were benign and 19 (30.2%) were malignant.
  • Symptomatic presentation and the impression of a nonpleural tumor by imaging study were found to be related to a malignant pathologic diagnosis.
  • The radiologic impression of solitary fibrous tumors of the pleura was also related to mass excision only.
  • [MeSH-major] Neoplasms, Fibrous Tissue / surgery. Pleural Neoplasms / surgery. Thoracic Surgery, Video-Assisted. Thoracotomy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biopsy, Fine-Needle. Child. Child, Preschool. Female. Humans. Incidental Findings. Life Tables. Male. Middle Aged. Neoplasm Recurrence, Local. Retrospective Studies. Sternum / surgery. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15620963.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 17
  •  go-up   go-down


21. Creaney J, Yeoman D, Demelker Y, Segal A, Musk AW, Skates SJ, Robinson BW: Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma. J Thorac Oncol; 2008 Aug;3(8):851-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: There is increasing interest in identifying a blood-based marker for the asbestos-related tumor, malignant mesothelioma.
  • The purpose of the current study was to directly compare these biomarkers in the same sample population, determining their sensitivity and specificity in establishing a diagnosis, and to determine if diagnostic accuracy for mesothelioma is improved by combining the data from all three markers.
  • METHODS: Serum levels of mesothelin, MPF and osteopontin were determined by commercially available assays in 66 samples from patients with pleural malignant mesothelioma, 20 healthy individuals, 21 patients with asbestos-related lung or pleural disease, 30 patients presenting with benign pleural effusions and 30 patients with other malignancies.
  • At a level of specificity of 95% relative to healthy controls and patients with benign asbestos related disease, the sensitivity for mesothelioma was 34% for MPF, 47% for osteopontin and 73% for mesothelin.
  • Osteopontin and MPF were unable to differentiate patients with mesothelioma from patients with other malignancies or those presenting with transudative pleural effusions.
  • CONCLUSION: Serum mesothelin remains the most specific marker for the diagnosis of mesothelioma.
  • [MeSH-major] Biomarkers, Tumor / blood. Membrane Glycoproteins / blood. Mesothelioma / blood. Osteopontin / blood. Pleural Neoplasms / blood
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, Neoplasm / blood. Female. GPI-Linked Proteins. Humans. Male. Middle Aged. Prognosis. ROC Curve. Sensitivity and Specificity. Survival Rate

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18670302.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / mesothelin; 106441-73-0 / Osteopontin
  •  go-up   go-down


22. van der Meij JJ, Boomars KA, van den Bosch JM, van Boven WJ, de Bruin PC, Seldenrijk CA: Primary pulmonary malignant meningioma. Ann Thorac Surg; 2005 Oct;80(4):1523-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary pulmonary meningiomas are relatively rare and mostly benign.
  • [MeSH-major] Bronchial Neoplasms / diagnosis. Bronchial Neoplasms / pathology. Meningioma / diagnosis. Meningioma / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Esophageal Neoplasms / pathology. Female. Humans. Liver Neoplasms / secondary. Magnetic Resonance Imaging. Meningeal Neoplasms / diagnosis. Neoplasm Invasiveness. Pleural Neoplasms / pathology. Treatment Outcome

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16181912.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


23. Scherpereel A, Grigoriu B, Conti M, Gey T, Grégoire M, Copin MC, Devos P, Chahine B, Porte H, Lassalle P: Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma. Am J Respir Crit Care Med; 2006 May 15;173(10):1155-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma.
  • BACKGROUND: Diagnosis of malignant pleural mesothelioma is a challenging issue.
  • Potential markers in mesothelioma diagnosis include soluble mesothelin-related peptides (SMRPs) and osteopontin, but no subsequent validation has been published yet.
  • METHODS: We prospectively evaluated SMRPs in serum and pleural effusion from patients with mesothelioma (n = 74), pleural metastasis of carcinomas (n = 35), or benign pleural lesions associated with asbestos exposure (n = 28), recruited when first suspected for mesothelioma.
  • FINDINGS: Mean serum SMRP level was higher in patients with mesothelioma (2.05 +/- 2.57 nM/L [median +/- interquartile range]) than in patients with metastasis (1.02 +/- 1.79 nM/L) or benign lesions (0.55 +/- 0.59 nM/L).
  • The area under the receiver operating characteristic curve (AUC) for serum SMRP was 0.872 for differentiating mesothelioma and benign lesions, cut-off = 0.93 nM/L (sensitivity = 80%, specificity = 82.6%).
  • SMRP values in pleural fluid were higher than in serum in all groups (mesothelioma: 46.1 +/- 83.2 nM/L; benign lesions: 6.4 +/- 11.1 nM/L; metastasis: 6.36 +/- 21.73 nM/L).
  • The AUC for pleural SMRP-differentiating benign lesions and mesothelioma was 0.831, cut-off = 10.4 nM/L (sensitivity = 76.7%, specificity = 76.2%).
  • The AUC for pleural SMRP-differentiating metastasis and mesothelioma was 0.793.
  • INTERPRETATION: We show that SMRPs may be a promising marker for mesothelioma diagnosis when measured either in serum or pleural fluid.
  • The diagnostic value of SMRPs was similar in both types of samples, but pleural fluid SMRPs may better discriminate mesothelioma from pleural metastasis.
  • [MeSH-major] Asbestosis / pathology. Membrane Glycoproteins / metabolism. Mesothelioma / pathology. Pleural Effusion, Malignant / diagnosis. Pleural Neoplasms / pathology. Sialoglycoproteins / metabolism
  • [MeSH-minor] Aged. Analysis of Variance. Area Under Curve. Biomarkers, Tumor / analysis. Diagnosis, Differential. Disease Progression. Female. GPI-Linked Proteins. Humans. Male. Middle Aged. Neoplasm Staging. Osteopontin. Prognosis. Prospective Studies. Sensitivity and Specificity. Solubility. Survival Analysis

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16456138.001).
  • [ISSN] 1073-449X
  • [Journal-full-title] American journal of respiratory and critical care medicine
  • [ISO-abbreviation] Am. J. Respir. Crit. Care Med.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / SPP1 protein, human; 0 / Sialoglycoproteins; 0 / mesothelin; 106441-73-0 / Osteopontin
  •  go-up   go-down


24. Lin H, Qiu SY, Sun SH: [Clinical value of CYFRA 21-1, HER-2/neu and NSE in differential diagnosis of pleural effusion]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2010 Aug;26(8):767-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical value of CYFRA 21-1, HER-2/neu and NSE in differential diagnosis of pleural effusion].
  • AIM: To explore the clinical value of CYFRA 21-1, HER-2/neu and NSE as tumor markers for differential diagnosis of malignant and benign pleural effusion.
  • METHODS: Radioimmunoassay and ELISA were used to detect the serum and effusion levels of CYFRA 21-1, HER-2/neu and NSE in 62 patients with malignat pleural effusion and 48 patients with benign pleural effusion.
  • RESULTS: The levels of CYFRA 21-1, HER-2/neu and NSE in serum and pleural effusion in malignant groups were significant higher than those in benign group (P < 0.01).The levels of CYFRA 21-1, HER-2/neu and NSE in pleural effusion were obviously higher than those in serum (P < 0.01 or 0.05).
  • The cut off value of NSE in serum was 11.40 μg/L, While the cut off value of NSE in pleural effusion was 16.47 μg/L.
  • The cut off values of CYFRA 21-1 in serum and in pleural effusion were 4.94 μg/L and 7.70 μg/L respectively.
  • The cut off values of HER-2/neu in serum and in pleural effusion were 2.50 μg/L and 3.50 μg/L, respectively.
  • Independent examination of the levels of CYFRA 21-1, HER-2/neu and NSE in serum and pleural effusion showed that the area under ROC curve was (0.852, 0.932), (0.867, 0.887) and (0.773, 0.846), respectively.
  • CONCLUSION: The detection of CYFRA 21-1, HER-2/neu and NSE in pleural effusion has certain clinical significance in differential diagnosis of malignant and benign effusions.
  • Given the limitation of single index, comprehensive application of multiple indexes may increase the accuracy of diagnosis.
  • [MeSH-major] Antigens, Neoplasm. Diagnostic Techniques and Procedures. Keratin-19. Phosphopyruvate Hydratase. Pleural Effusion / diagnosis. Receptor, ErbB-2
  • [MeSH-minor] Adult. Biomarkers, Tumor / blood. Diagnosis, Differential. Female. Humans. Male. Middle Aged. ROC Curve. Young Adult

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20619104.001).
  • [ISSN] 1007-8738
  • [Journal-full-title] Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology
  • [ISO-abbreviation] Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Keratin-19; 0 / antigen CYFRA21.1; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2; EC 4.2.1.11 / Phosphopyruvate Hydratase
  •  go-up   go-down


25. Reich R, Vintman L, Nielsen S, Kaern J, Bedrossian C, Berner A, Davidson B: Differential expression of the 67 kilodalton laminin receptor in epithelioid malignant mesothelioma and carcinomas that spread to serosal cavities. Diagn Cytopathol; 2005 Nov;33(5):332-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant mesothelioma (MM) is a locally aggressive and highly lethal tumor of serosal cavities that is rarely associated with clinically detectable metastasis to distant organs.
  • Nine benign effusions that were additionally studied for protein expression were uniformly negative, as were all reactive mesothelial cells in malignant effusions.
  • Our results suggest that the 67-kd LR may aid in the differential diagnosis between metastatic carcinoma, mainly of ovarian origin, and MM.
  • They additionally suggest that the failure of MM to express the 67-kd LR protein, as opposed to the frequent expression in carcinomas with proven metastatic capacity, may be one of the factors contributing to the reduced ability of the former tumor to metastasize to distant organs.
  • [MeSH-major] Adenocarcinoma / metabolism. Ascitic Fluid / metabolism. Mesothelioma / metabolism. Pleural Effusion, Malignant / metabolism. Receptors, Laminin / biosynthesis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Female. Humans. Male. Middle Aged. Molecular Weight. Neoplasm Invasiveness. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / pathology. RNA, Messenger / biosynthesis

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16240397.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Receptors, Laminin
  •  go-up   go-down


26. Sayed DM, el-Attar MM, Hussein AA: Evaluation of flow cytometric immunophenotyping and DNA analysis for detection of malignant cells in serosal cavity fluids. Diagn Cytopathol; 2009 Jul;37(7):498-504
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The serosal cavities are frequent sites of tumor metastasis.
  • In this study, we aimed to assess the diagnostic accuracy of FCM immunophenotyping and DNA in comparison with serum tumor markers and classic cytology for detection of malignant cells in pleural and ascitic fluids.
  • The mean of DI differed statistically in patients with malignant effusions than in benign one.
  • [MeSH-major] DNA, Neoplasm / genetics. Flow Cytometry / methods. Neoplasm Proteins / genetics. Neoplasm Proteins / metabolism. Neoplasms / genetics. Neoplasms / metabolism. Neoplasms / pathology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 Wiley-Liss, Inc.
  • (PMID = 19217060.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Neoplasm Proteins
  •  go-up   go-down


27. Takagi M, Kuwano K, Watanabe K, Akiba T: A case of recurrence and rapid growth of pleural solitary fibrous tumor 8 years after initial surgery. Ann Thorac Cardiovasc Surg; 2009 Jun;15(3):178-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of recurrence and rapid growth of pleural solitary fibrous tumor 8 years after initial surgery.
  • A 69-year-old woman underwent resection of a solitary fibrous tumor (SFT) of the left pleura in April 1997 and of locally recurrent SFT in the left thoracic cavity in September 2003.
  • A postoperative follow-up chest CT scan in March 2005 revealed pleural thickening at two sites of the left thoracic cavity.
  • The two resected tumors were benign SFT, and were diagnosed as locally recurrent SFT in the left thoracic cavity.
  • It has been reported that despite its benign histopathology, pleural SFT recurs more than once after surgery, and the interval between recurrences tends to shorten from the second recurrence.
  • In this patient, the tumor recurred twice and showed a rapidly enlarging tendency at the time of the second recurrence, suggesting the need for careful follow-up at short intervals.
  • [MeSH-major] Neoplasm Recurrence, Local. Pleural Neoplasms / surgery. Pulmonary Surgical Procedures. Solitary Fibrous Tumor, Pleural / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19597394.001).
  • [ISSN] 2186-1005
  • [Journal-full-title] Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia
  • [ISO-abbreviation] Ann Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


28. Lu C, Ji Y, Shan F, Guo W, Ding J, Ge D: Solitary fibrous tumor of the pleura: an analysis of 13 cases. World J Surg; 2008 Aug;32(8):1663-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary fibrous tumor of the pleura: an analysis of 13 cases.
  • BACKGROUND: Solitary fibrous tumor of the pleura is a rare soft-tissue tumor.
  • In search of appropriate diagnosis and treatment methods, we present our experience with 13 patients.
  • Seven tumors were malignant and the other six were benign.
  • Immunohistochemical staining showed nestin was positive in three malignant solitary fibrous tumors of pleura (3/7), which were negative for CD34.
  • CONCLUSION: Ultrasonography-guided core needle biopsy combined with immunohistochemical analysis might be a safe and rapid method to provide a confirmatory diagnosis before resection.
  • We speculate that CD34-negative and nestin-positive might be a malignant marker for solitary fibrous tumor of pleura.
  • [MeSH-major] Neoplasms, Fibrous Tissue / diagnosis. Neoplasms, Fibrous Tissue / surgery. Pleural Neoplasms / diagnosis. Pleural Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Biopsy, Needle / methods. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Metastasis. Radiography, Thoracic. Thoracic Surgery, Video-Assisted. Tomography, X-Ray Computed. Ultrasonography, Interventional

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 1998 May;32(5):423-32 [9639117.001]
  • [Cites] Am J Surg Pathol. 1989 Aug;13(8):640-58 [2665534.001]
  • [Cites] Semin Thorac Cardiovasc Surg. 2003 Jul;15(3):305-9 [12973709.001]
  • [Cites] Ann Thorac Surg. 2000 Dec;70(6):1808-12 [11156076.001]
  • [Cites] Ann Thorac Surg. 2002 Jul;74(1):285-93 [12118790.001]
  • [Cites] Eur J Cardiothorac Surg. 1998 Nov;14(5):453-9 [9860200.001]
  • [Cites] Am J Surg Pathol. 1994 Aug;18(8):814-20 [7518652.001]
  • [Cites] Ultrastruct Pathol. 1991 Jul-Oct;15(4-5):489-92 [1755106.001]
  • [Cites] J Comput Assist Tomogr. 2002 Mar-Apr;26(2):174-9 [11884769.001]
  • [Cites] Cancer. 1981 Jun 1;47(11):2678-89 [7260861.001]
  • [Cites] Jpn J Clin Oncol. 1998 Feb;28(2):86-91 [9544821.001]
  • [Cites] Cancer Control. 2006 Oct;13(4):264-9 [17075563.001]
  • [Cites] Differentiation. 1997 Feb;61(3):151-9 [9084133.001]
  • [Cites] Chest. 2000 Mar;117(3):897-900 [10713024.001]
  • [Cites] Hum Pathol. 1995 Apr;26(4):428-31 [7535740.001]
  • [Cites] Acta Neuropathol. 2001 Oct;102(4):349-54 [11603810.001]
  • [Cites] Eur J Cardiothorac Surg. 2002 Jun;21(6):1087-93 [12048090.001]
  • [Cites] Chest. 1997 Nov 5;112(5):1424-8 [9367487.001]
  • [Cites] Chest. 2004 Mar;125(3):1144-7 [15006980.001]
  • [Cites] Eur J Cardiothorac Surg. 1997 Dec;12 (6):928-30 [9489884.001]
  • (PMID = 18427887.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 20
  •  go-up   go-down


29. Kyle CC, Wingo MS, Carey RI, Leveillee RJ, Bird VG: Diagnostic yield of renal biopsy immediately prior to laparoscopic radiofrequency ablation: a multicenter study. J Endourol; 2008 Oct;22(10):2291-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mean tumor size was 3.0 cm (range 1.0-6.9).
  • Final pathology revealed renal cell carcinoma in 95, oncocytic neoplasm in 26, and angiomyolipoma in 9.8 patients were considered to have nondiagnostic biopsies.
  • In this group, final pathology revealed benign cysts in 3, inconclusive specimens in 3, fibrosis in 1, and normal tissue in 1.
  • Hence, a clear diagnosis was possible in 130 of 138 patients, which is 94.2%.
  • Eight patients had perioperative complications, including low-grade fevers (2) perirenal/retroperitonal hematoma (2), pleural tear/pneumothorax (2), CHF exacerbation, and wound infection.

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18937593.001).
  • [ISSN] 1557-900X
  • [Journal-full-title] Journal of endourology
  • [ISO-abbreviation] J. Endourol.
  • [Language] ENG
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


30. Greillier L, Roll P, Barlesi F, Robaglia-Schlupp A, Fraticelli A, Cau P, Astoul P: [Role of DNA microarrays in the diagnosis of pleural exudates: a feasibility study]. Rev Mal Respir; 2007 Sep;24(7):859-67
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Role of DNA microarrays in the diagnosis of pleural exudates: a feasibility study].
  • [Transliterated title] Apport des puces à ADN dans le diagnostic étiologique des pleurésies: étude de faisabilité
  • INTRODUCTION: Establishing the cause of exudative pleural effusions is sometimes difficult, especially in the context of possible malignant pleural mesothelioma (MPM).
  • The aim of this study was to determine the feasibility and the diagnostic contribution of genomic analysis of cells contained in pleural fluid, using DNA microarray techniques.
  • METHODS: Patients with pleural effusion requiring diagnostic thoracocentesis were eligible to participate in the study.
  • Five hundred mls of pleural fluid were then collected.
  • RNA was extracted from pleural fluid cells and its integrity was assessed.
  • RESULTS: Seventeen patients were included (4 MPM, 8 secondary malignant pleurisies, 5 benign pleurisies).
  • Taking into account the results of control experiments, gene expression study from pleural fluid was reproducible.
  • CONCLUSIONS: Gene expression study of cells from pleural fluid is feasible but remains difficult, essentially in relationship with RNA weakness.
  • [MeSH-major] Oligonucleotide Array Sequence Analysis. Pleural Effusion / diagnosis
  • [MeSH-minor] Aged. Asbestosis / complications. DNA, Neoplasm / genetics. Feasibility Studies. Female. Gene Expression Profiling. Humans. Male. Mesothelioma / diagnosis. Middle Aged. Pleural Effusion, Malignant / diagnosis. Pleural Effusion, Malignant / genetics. Pleural Neoplasms / diagnosis. Pleural Neoplasms / secondary. Pleurisy / diagnosis. Prospective Studies. RNA, Neoplasm / genetics. Smoking

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Rev Mal Respir. 2007 Sep;24(7):821-4 [17925663.001]
  • (PMID = 17925668.001).
  • [ISSN] 0761-8425
  • [Journal-full-title] Revue des maladies respiratoires
  • [ISO-abbreviation] Rev Mal Respir
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / RNA, Neoplasm
  •  go-up   go-down


31. Wheeler YY, Burroughs F, Li QK: Fine-needle aspiration of a well-differentiated papillary mesothelioma in the inguinal hernia sac: A case report and review of literature. Diagn Cytopathol; 2009 Oct;37(10):748-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • WDPM may be difficult to diagnose and differentiate from benign reactive mesothelial cells and other malignant neoplasm on cytology specimens due to the presence of papillary or tubulopapillary clusters of tumor cells.
  • Tumor cells show minimal cytological atypia.
  • The differential diagnoses are broad and include reactive mesothelial cells, WDPM, and other malignant neoplasm.
  • It is important to recognize this entity in the differential diagnosis, because the clinical management of WDPM is quite different from that of malignant neoplasm.
  • On the basis of the published data in the literature, it suggests that in male patients, the WDPM occurs predominantly in pleural cavity of older men in their 50s, and about half of the patients have history of asbestos exposure.

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • (PMID = 19373910.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 26
  •  go-up   go-down


32. Torres-Olivera FJ, Vargas MT, Torres-Gómez FJ, Trigo I, Díaz M, González-Cámpora R: Cytogenetic, fluorescence in situ hybridization, and immunohistochemistry studies in a malignant pleural solitary fibrous tumor. Cancer Genet Cytogenet; 2009 Mar;189(2):122-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytogenetic, fluorescence in situ hybridization, and immunohistochemistry studies in a malignant pleural solitary fibrous tumor.
  • Pleural solitary fibrous tumor is a normally benign fibroblastic neoplasm; its recurrences and metastasis are associated with clinical and morphological characteristics of variable interpretation and efficacy of surgical treatment.
  • Immunohistochemistry techniques have contributed decisively to the correct diagnosis of the lesion and define its prognosis.
  • In the present case, cytogenetic and fluorescence in situ hybridization analyses revealed multiple chromosomal aberrations, including a del(9)(q21qter) and a marker chromosome ish der(9)(ABL+).
  • [MeSH-major] Solitary Fibrous Tumor, Pleural / diagnosis

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19215794.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Watanabe T, Sato N, Miyamoto A, Kaimori M, Imai T: [Recurrence of thymoma as pleural dissemination 23-years after surgery]. Kyobu Geka; 2009 Jan;62(1):79-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Recurrence of thymoma as pleural dissemination 23-years after surgery].
  • We thought that it was a benign chest wall tumor such as a neurogenic tumor by the findings of the chest computed tomography (CT).
  • Resection of the tumor was performed.
  • Neurogenic tumor was suspected by the frozen section.
  • Since she had undergone thymothymectomy 23-years ago, the tumor was considered to be a pleural recurrence of thymoma.
  • We thoroughly checked the chest CT again, and detected another tumor at the right of the thoracic vertebra.
  • Third surgery was performed and the tumor was resected.
  • We experienced recurrence of thymoma as pleural dissemination 23-years after surgery.
  • Thymomas are low-grade malignant tumor, but long-term clinical follow-up is necessary.
  • [MeSH-major] Pleural Neoplasms / secondary. Thymoma / pathology. Thymus Neoplasms / pathology
  • [MeSH-minor] Female. Humans. Middle Aged. Neoplasm Seeding

  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19195191.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


34. Ramírez GA, Spattini G, Altimira J, García B, Vilafranca M: Clinical and histopathological features of a thymolipoma in a dog. J Vet Diagn Invest; 2008 May;20(3):360-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This study presents a case of a canine thymolipoma, which is a rare, slow-growing, benign tumor of the thymus composed of mature adipose tissue and thymic tissue.
  • Radiology revealed pleural effusion and a mediastinal mass with a fatty appearance.
  • To the authors' knowledge, this is the first description of this uncommon neoplasm in a dog.
  • The possible histogenesis for this neoplasia in a dog is also discussed.
  • [MeSH-major] Dog Diseases / diagnosis. Lipoma / veterinary. Thymus Neoplasms / veterinary

  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18460628.001).
  • [ISSN] 1040-6387
  • [Journal-full-title] Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc
  • [ISO-abbreviation] J. Vet. Diagn. Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Radotra B, Awasthi A, Joshi K, Das A: Histopatholgical spectrum of thymic neoplasms: twelve-year experience at a referral hospital in north India. Indian J Pathol Microbiol; 2006 Jan;49(1):1-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A total of 96 thymectomy specimens were received during the study period (1992-2004), which consisted of 54 neoplasms and 42 benign lesions.
  • On staging, all cases of mixed and predominantly cortical subtype were stage 1 whereas one medullary and 2 cortical thymomas and 4 well differentiated thymic carcinoma (WDTC) showed pleural and pericardial invasion (stage III).
  • [MeSH-minor] Adolescent. Adult. Aged. Carcinoid Tumor / pathology. Carcinoma / pathology. Child. Child, Preschool. Female. Humans. India. Lipoma / pathology. Male. Middle Aged. Myasthenia Gravis. Neoplasm Staging. Red-Cell Aplasia, Pure. Thymectomy. Thymoma / pathology. Thymus Gland / pathology

  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16625962.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  •  go-up   go-down


36. Krishnadas R, Froeschle PO, Berrisford RG: Recurrence and malignant transformation in solitary fibrous tumour of the pleura. Thorac Cardiovasc Surg; 2006 Feb;54(1):65-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrence and malignant transformation in solitary fibrous tumour of the pleura.
  • Solitary fibrous tumours of the pleura are mesenchymal neoplasms and recurrence with malignant progression after complete resection rarely occurs.
  • Even though the vast majority of these tumours are benign, complete resection as well as clinical and radiological follow-up are highly recommended because of the potentially adverse biological behaviour and the lack of radical treatment options other than surgery.
  • [MeSH-major] Neoplasm Recurrence, Local. Neoplasms, Fibrous Tissue / pathology. Pleural Neoplasms / pathology
  • [MeSH-minor] Aged. Biomarkers, Tumor / blood. Bronchoscopy. Female. Humans. Immunohistochemistry. Neoplasm Staging. Thoracotomy. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16485194.001).
  • [ISSN] 0171-6425
  • [Journal-full-title] The Thoracic and cardiovascular surgeon
  • [ISO-abbreviation] Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


37. Martínez Martínez P, Moldes Rodríguez M, Moreno Mata N, Simón Adiego C, Cebollero Presmanes M, González Aragoneses F: [Immunohistochemistry and surgical approaches in solitary fibrous tumor of the pleura]. Cir Esp; 2007 Mar;81(3):155-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Immunohistochemistry and surgical approaches in solitary fibrous tumor of the pleura].
  • [Transliterated title] Inmunohistoquímica y vías de abordaje en el tumor fibroso pleural.
  • Solitary fibrous tumor of the pleura (SFTP) is a rare, benign, slow-growing neoplasm that arises from the submesothelial cells of the pleura.
  • Usually, resection of the tumor and adjacent structures are sufficient for resolution.
  • Only four patients were symptomatic at diagnosis.
  • Because of the malignant potential of this tumor, long-term follow-up is mandatory.
  • [MeSH-major] Neoplasms, Fibrous Tissue / immunology. Neoplasms, Fibrous Tissue / surgery. Pleural Neoplasms / immunology. Pleural Neoplasms / surgery. Thoracic Surgery, Video-Assisted / instrumentation
  • [MeSH-minor] Adult. Aged. Antigens, CD34 / immunology. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Male. Mesothelioma / immunology. Mesothelioma / pathology. Mesothelioma / surgery. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17349242.001).
  • [ISSN] 0009-739X
  • [Journal-full-title] Cirugía española
  • [ISO-abbreviation] Cir Esp
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antigens, CD34
  •  go-up   go-down


38. King J, Thatcher N, Pickering C, Hasleton P: Sensitivity and specificity of immunohistochemical antibodies used to distinguish between benign and malignant pleural disease: a systematic review of published reports. Histopathology; 2006 Dec;49(6):561-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sensitivity and specificity of immunohistochemical antibodies used to distinguish between benign and malignant pleural disease: a systematic review of published reports.
  • AIMS: A systematic review of published reports that have evaluated the ability of immunohistochemistry and argyrophil nucleolar organizing region (AgNOR) staining to distinguish between benign and malignant pleural disease.
  • A high MCM2 labelling index also differentiated between benign and malignant pleural disease.
  • The diagnostic importance of histological features seen on plain tissue sections is emphasized as vital for correctly differentiating between benign pleural disease and malignant pleural mesothelioma.
  • [MeSH-major] Antigens, Neoplasm / immunology. Immunohistochemistry / methods. Mesothelioma / diagnosis. Pleural Neoplasms / diagnosis. Silver Staining
  • [MeSH-minor] Antigens, Nuclear. Biomarkers, Tumor / analysis. Diagnosis, Differential. Humans. Nuclear Proteins. Nucleolus Organizer Region / pathology. Predictive Value of Tests. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17163840.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Antigens, Nuclear; 0 / Biomarkers, Tumor; 0 / Nuclear Proteins; 0 / nucleolar organizer region associated proteins
  • [Number-of-references] 33
  •  go-up   go-down


39. Liu YQ, Zhang HL, Gao WJ, Lan X, Yuan BJ, Zou JM: [Value of tumor markers series of hydrothorax in differential diagnosis of pleural effusion]. Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2008 Jan;26(1):34-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Value of tumor markers series of hydrothorax in differential diagnosis of pleural effusion].
  • OBJECTIVE: To investigate the clinical value of pleural effusion lung ProGRP, neuron specific enolase (NSE), cytokeratin fragment 19 (CYFRA21-1), carcino-embryonic antigen (CEA), carbohydrate antigen 153 (CA153), carbohydrate antigen 19 - 9 (CA19-9) in differential diagnosis and histological typing of malignant pleural effusion caused by lung cancer.
  • The patients with benign pleural effusion served as the controls (n = 30).
  • The diagnostic value of pleural effusion ProGRP, NSE, CYFRA21-1, CEA, CA153 and CA19-9 was compared for each group.
  • RESULTS: Youden index and the accurate rate of pleural effusion ProGRP + NSE (sequence test) were the highest in the diagnosis of malignant hydrothorax caused by SCLC.
  • CEA + CA153 + CA19-9 (sequence test) was the highest in the diagnosis of malignant hydrothorax caused by adenocarcinoma.
  • CYFRA21-1 + CEA + CA153 (on parallel test) were the highest in the diagnosis of malignant hydrothorax caused by squamous cell carcinoma.
  • CONCLUSION: The first pleural effusion tumor markers of malignant hydrothorax caused by the SCLC, adenocarcinoma of lung, and lung squamous cell carcinoma are ProGRP, CEA and CYFRA21-1, respectively.
  • The best combinations of pleural effusion tumor marker in diagnosis of malignant hydrothorax caused by the SCLC, adenocarcinoma of lung, lung squamous cell carcinoma and lung cancer are the combined detection of ProGRP + NSE (sequence test), combined detection of CEA + CA153 + CA19-9 (sequence test), the combined detection of CYFRA21-1 + CEA + CA153 (on parallel test) and ProGRP + CYFRA21-1 + CEA (on parallel test), respectively.
  • [MeSH-major] Antigens, Neoplasm / analysis. Biomarkers, Tumor / analysis. Lung Neoplasms / diagnosis. Pleural Effusion, Malignant / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. CA-19-9 Antigen / analysis. Diagnosis, Differential. Female. Humans. Keratin-19 / analysis. Male. Middle Aged. Peptide Fragments / analysis. Recombinant Proteins / analysis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18302890.001).
  • [ISSN] 1001-9391
  • [Journal-full-title] Zhonghua lao dong wei sheng zhi ye bing za zhi = Zhonghua laodong weisheng zhiyebing zazhi = Chinese journal of industrial hygiene and occupational diseases
  • [ISO-abbreviation] Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi
  • [Language] chi
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / CA-19-9 Antigen; 0 / CA153 protein, human; 0 / Keratin-19; 0 / Peptide Fragments; 0 / Recombinant Proteins; 0 / antigen CYFRA21.1; 0 / pro-gastrin-releasing peptide (31-98)
  •  go-up   go-down


40. Gill RR, Gerbaudo VH, Sugarbaker DJ, Hatabu H: Current trends in radiologic management of malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg; 2009;21(2):111-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current trends in radiologic management of malignant pleural mesothelioma.
  • Malignant pleural mesothelioma (MPM) is an aggressive pleural tumor with a complex growth pattern.
  • Imaging plays a crucial role in diagnosis and management.
  • Magnetic resonance imaging (MRI) is superior to CT, both in the differentiation of malignant from benign pleural disease and in the assessment of chest wall and diaphragmatic involvement.
  • Perfusion and diffusion MRI are promising new techniques for the assessment of tumor cellularity and microvasculature and can be used for quantitative and qualitative assessment of treatment response.
  • Fluorodeoxyglucose positron emission tomography (FDG-PET) is useful for the differentiation of benign from malignant lesions, for staging, and for monitoring response to therapy.
  • [MeSH-major] Magnetic Resonance Imaging / trends. Mesothelioma / diagnosis. Pleural Neoplasms / diagnosis. Positron-Emission Tomography / trends. Tomography, X-Ray Computed / trends
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Fluorodeoxyglucose F18. Humans. Lymphatic Metastasis. Neoplasm Invasiveness. Neoplasm Staging. Palliative Care. Pleural Effusion, Malignant / diagnosis. Predictive Value of Tests. Radiopharmaceuticals. Thoracic Surgical Procedures. Treatment Outcome

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19822282.001).
  • [ISSN] 1043-0679
  • [Journal-full-title] Seminars in thoracic and cardiovascular surgery
  • [ISO-abbreviation] Semin. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R21 CA116271
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Number-of-references] 30
  •  go-up   go-down


41. Alvarado-Cabrero I, Hernández S, Kelly G J, Cuenca-Buele S: [Pleura's solitary fibrous tumor. Clinical pathology analysis of 17 cases]. Rev Med Inst Mex Seguro Soc; 2006 Sep-Oct;44(5):397-402
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pleura's solitary fibrous tumor. Clinical pathology analysis of 17 cases].
  • [Transliterated title] Tumor fibroso solitario de la pleura. Análisis clínico-patológico de 17 casos.
  • INTRODUCTION: Solitary fibrous tumor of the pleura (SFTP) is a rare neoplasm that usually originates from the visceral pleura, but it can occur in a wide range of tissues.
  • Approximately 12% of pleural cases are malignant tumors and surgical excision usually become curative.
  • MATERIAL AND METHODS: We did a retrospective review of the patients who had primary pleural tumors from January 1995 to August 2005.
  • RESULTS: Among a total of 94 primary pleural tumors, 17 patients were enrolled in this study, 8 men and 9 women, with a mean age of 63 years.
  • Thirteen cases (76%) were benign and four cases (23%) were malignant.
  • CONCLUSIONS: SFTP shows a benign biologic outcome in most of the cases.
  • There are some histological characteristics that led to distinguish between benign and malign neoplasm.
  • [MeSH-major] Neoplasms, Fibrous Tissue / pathology. Pleural Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17207398.001).
  • [ISSN] 0443-5117
  • [Journal-full-title] Revista médica del Instituto Mexicano del Seguro Social
  • [ISO-abbreviation] Rev Med Inst Mex Seguro Soc
  • [Language] spa
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


42. Ikeda K, Tate G, Suzuki T, Kitamura T, Mitsuya T: IMP3/L523S, a novel immunocytochemical marker that distinguishes benign and malignant cells: the expression profiles of IMP3/L523S in effusion cytology. Hum Pathol; 2010 May;41(5):745-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IMP3/L523S, a novel immunocytochemical marker that distinguishes benign and malignant cells: the expression profiles of IMP3/L523S in effusion cytology.
  • A total of 229 cases of pleural and peritoneal effusion cytospecimens were evaluated for the study, including 39 benign effusions with reactive mesothelial cells and 190 metastatic malignant effusions.
  • The overall specificity for the diagnosis of malignancy was 94.9%, whereas the sensitivity was 72.6%.
  • In the peritoneal effusions, the sensitivity for the diagnosis of metastatic adenocarcinoma to distinguish reactive mesothelial cells was 92.3%.
  • [MeSH-major] Adenocarcinoma / metabolism. Ascitic Fluid / metabolism. Biomarkers, Tumor / metabolism. Mesothelioma / metabolism. Neoplasm Proteins / metabolism. Pleural Effusion, Malignant / metabolism. RNA-Binding Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20060157.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / IMP3 protein, human; 0 / Neoplasm Proteins; 0 / RNA-Binding Proteins
  •  go-up   go-down


43. Bodtger U, Pedersen JH, Skov BG, Clementsen P: Giant solitary fibrous tumour of the pleura: a rare but usually benign intrathoracic neoplasm. Clin Respir J; 2009 Apr;3(2):109-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant solitary fibrous tumour of the pleura: a rare but usually benign intrathoracic neoplasm.
  • METHODS: A case report of an 83-year-old women with progressing dyspnoea secondary to a huge left-side neoplasm.
  • RESULTS: Work-up reveal an FEV(1) of 0.4 L, and a giant solitary fibrous tumor of the pleura.
  • The tumor was surgically removed in toto without complications: weighting approximately 3 kg, and benign histology.
  • CONCLUSION: Safe and curative surgery is possible in patients with extrapulmonal neoplasm despite poor FEV(1).
  • [MeSH-major] Solitary Fibrous Tumor, Pleural / pathology. Solitary Fibrous Tumor, Pleural / surgery. Thoracic Surgical Procedures / methods
  • [MeSH-minor] Aged, 80 and over. Biopsy, Needle. Dyspnea / diagnosis. Dyspnea / etiology. Female. Follow-Up Studies. Humans. Immunohistochemistry. Postoperative Care / methods. Preoperative Care / methods. Radiography, Thoracic. Severity of Illness Index. Thoracotomy / methods. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20298386.001).
  • [ISSN] 1752-699X
  • [Journal-full-title] The clinical respiratory journal
  • [ISO-abbreviation] Clin Respir J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


44. Solli P, Spaggiari L: Indications and developments of video-assisted thoracic surgery in the treatment of lung cancer. Oncologist; 2007 Oct;12(10):1205-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The VATS approach is presently used in many intrathoracic disorders, but while well established in benign chest disease, its role continues to evolve regarding the management of lung cancer.
  • It is currently considered for the evaluation and treatment of suspected (or known) pleural effusion and in the diagnosis of indeterminate pulmonary nodules, and it has a complementary role to standard cervical mediastinoscopy in the invasive staging of mediastinal lymph nodes.
  • [MeSH-minor] Humans. Minimally Invasive Surgical Procedures. Neoplasm Staging. Patient Care Planning. Prognosis

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17962614.001).
  • [ISSN] 1083-7159
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 105
  •  go-up   go-down


45. Huang F, Wang XL, Yang L, Yin BX, Geng Y, Li TT: [Clinical value of combined determination of serum and pleural effusion level of CEA,CYFRA21-1, TPS in the diagnosis of lung cancer]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2008 Apr;24(4):370-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical value of combined determination of serum and pleural effusion level of CEA,CYFRA21-1, TPS in the diagnosis of lung cancer].
  • AIM: To study the clinical value of combined determination of carcinoembryonic antigen (CEA), cytokeratin-19-fragments (CYFRA21-1) and tissue polypeptide specific antigen (TPS) levels in both serum and pleural effusion in the diagnosis of lung cancer.
  • METHODS: The levels of CEA, CYFRA21-1 and TPS in serum and pleural effusion were measured in 78 patients with lung cancer and 45 patients with benign lung disease by using electrochemiluminescence and ELISA methods respectively.
  • RESULTS: The levels of CEA, CYFRA21-1 and TPS in pleural effusion of patients with lung cancer were much higher than those with benign lung disease (P<0.01).
  • The levels of CEA and TPS in serum of patients with lung cancer were much higher than those with benign lung disease (P<0.05, P<0.01).
  • It was also found that the levels of these tumor markers in pleural effusion were higher and more sensitive than those in sera, especially TPS.
  • TPS showed the highest sensitivity in single tumor marker detection, and TPS+CYFRA21-1+ CEA showed the highest sensitivity and accuracy in combined tumor marker detection for diagnosis of lung cancer in pleural effusion.
  • CONCLUSION: The combined detection of CEA, CYFRA21-1 and TPS in pleural effusion showed higher sensitivity, better accuracy and higher clinical value than those in serum for diagnosis of lung cancer.
  • [MeSH-major] Antigens, Neoplasm / blood. Antigens, Neoplasm / metabolism. Carcinoembryonic Antigen / blood. Carcinoembryonic Antigen / metabolism. Keratin-19 / blood. Keratin-19 / metabolism. Lung Neoplasms / diagnosis. Peptides / blood. Pleural Effusion / metabolism

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18394347.001).
  • [ISSN] 1007-8738
  • [Journal-full-title] Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology
  • [ISO-abbreviation] Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Carcinoembryonic Antigen; 0 / Keratin-19; 0 / Peptides; 0 / antigen CYFRA21.1; 0 / tissue polypeptide specific antigen
  •  go-up   go-down


46. Mavi A, Lakhani P, Zhuang H, Gupta NC, Alavi A: Fluorodeoxyglucose-PET in characterizing solitary pulmonary nodules, assessing pleural diseases, and the initial staging, restaging, therapy planning, and monitoring response of lung cancer. Radiol Clin North Am; 2005 Jan;43(1):1-21, ix
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fluorodeoxyglucose-PET in characterizing solitary pulmonary nodules, assessing pleural diseases, and the initial staging, restaging, therapy planning, and monitoring response of lung cancer.
  • Fluorodeoxyglucose-PET imaging has secured an important role in the assessment and management of a multitude of pulmonary disorders, including solitary pulmonary nodules, lung cancer, and pleural diseases.
  • In this review, the authors present a growing body of evidence that demonstrates and supports the utility of FDG-PET in the differentiation of benign and malignant pulmonary nodules, the assessment of lung cancer in various stages of disease, and the characterization of pleural diseases.
  • [MeSH-major] Fluorodeoxyglucose F18. Lung Neoplasms / radionuclide imaging. Pleural Diseases / radionuclide imaging. Positron-Emission Tomography. Radiopharmaceuticals. Solitary Pulmonary Nodule / radionuclide imaging
  • [MeSH-minor] Diagnosis, Differential. Humans. Neoplasm Metastasis. Neoplasm Staging. Time Factors

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Pleural Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15693644.001).
  • [ISSN] 0033-8389
  • [Journal-full-title] Radiologic clinics of North America
  • [ISO-abbreviation] Radiol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Number-of-references] 145
  •  go-up   go-down


47. Roncella S, Ferro P, Franceschini MC, Bacigalupo B, Dessanti P, Sivori M, Carletti AM, Fontana V, Canessa PA, Pistillo MP, Fedeli F: Diagnosis and origin determination of malignant pleural effusions through the use of the breast cancer marker human mammaglobin. Diagn Mol Pathol; 2010 Jun;19(2):92-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis and origin determination of malignant pleural effusions through the use of the breast cancer marker human mammaglobin.
  • As was reported that human mammaglobin (hMAM) may be expressed in malignant pleural effusions (PEs), we investigated the relevance of hMAM reverse-transcriptase polymerase chain reaction (RT-PCR) for their diagnosis and determination of primary origin.
  • Two hundred and twenty-eight malignant (132 male, 96 female) and 185 benign (132 male, 53 female) PEs were investigated.
  • Statistical analyses evaluated the diagnostic performance parameters in all PEs and in cytologically negative malignant PEs, the association between hMAM and benign or malignant status by the direct index of correlation [diagnostic odds ratio (DOR)], chi test, and P value (P).
  • In the entire patient population, hMAM was detected in 45.6% and 5.4% of malignant and benign PEs, respectively, in the male group in 41.7% and 4.5% and in the female group in 51.0% and 7.5% of malignant and benign PEs, respectively.
  • Our results suggest that hMAM RT-PCR may provide information both in the diagnosis of PE and in the search for the primary site of neoplasia, either in male or female patients.
  • [MeSH-major] Breast Neoplasms / complications. Breast Neoplasms / diagnosis. Neoplasm Proteins / genetics. Pleural Effusion, Malignant / diagnosis. Pleural Effusion, Malignant / etiology. Reverse Transcriptase Polymerase Chain Reaction / methods. Uteroglobin / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor. Female. Humans. Male. Mammaglobin A. Middle Aged. United States. Young Adult

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20502186.001).
  • [ISSN] 1533-4066
  • [Journal-full-title] Diagnostic molecular pathology : the American journal of surgical pathology, part B
  • [ISO-abbreviation] Diagn. Mol. Pathol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mammaglobin A; 0 / Neoplasm Proteins; 0 / SCGB2A2 protein, human; 9060-09-7 / Uteroglobin
  •  go-up   go-down


48. Ohar JA, Ampleford EJ, Howard SE, Sterling DA: Identification of a mesothelioma phenotype. Respir Med; 2007 Mar;101(3):503-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Despite the strong association of asbestos exposure to mesothelioma, only a fraction of persons exposed develop this neoplasm which is characterized by long latency and shortened survival.
  • To identify a more extensive set of traits that would define a mesothelioma phenotype for the purpose of genetic analysis, we set to determine characteristics that distinguish mesothelioma patients from others exposed to asbestos and to identify factors that predict the presence of mesothelioma over other mesenchymal tumors of the peritoneum and carcinoma metastatic to the pleura.
  • We compared demographics in four asbestos-exposed groups (controls n=347, bronchogenic cancer n=67, mesothelioma n=179 and benign asbestos-induced lung disease (BALD) n=3757).
  • We found that compared to other asbestos-exposed groups, subjects with mesothelioma were younger at first asbestos exposure, had a greater risk of a second cancer diagnosis (odds ratio=3.29), had a longer disease latency, and had a greater risk of cancer among first-degree relatives (point estimate for risk 2.93; 95% CI 2.5-3.5).
  • Thoracic tumor location, work exposure and male gender were consistently associated with shortened survival (1.9+/-1.3 years).
  • We conclude that thoracic tumor location, work exposure, male gender, long latency, early age at first exposure, presence of a second cancer, and first-degree relative with cancer define a phenotype that sets mesothelioma patients with a short survival apart from other asbestos-exposed individuals.
  • [MeSH-minor] Age Factors. Aged. Educational Status. Family Health. Female. Humans. Male. Middle Aged. Neoplasms, Multiple Primary. Occupational Exposure / adverse effects. Peritoneal Neoplasms / genetics. Peritoneal Neoplasms / mortality. Phenotype. Pleural Neoplasms / genetics. Pleural Neoplasms / mortality. Risk Factors. Sex Factors. Smoking / adverse effects


49. Hanley KZ, Facik MS, Bourne PA, Yang Q, Spaulding BO, Bonfiglio TA, Xu H: Utility of anti-L523S antibody in the diagnosis of benign and malignant serous effusions. Cancer; 2008 Feb 25;114(1):49-56
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Utility of anti-L523S antibody in the diagnosis of benign and malignant serous effusions.
  • METHODS: Seventy-six cases with paraffin-embedded pleural, pericardial, and peritoneal serous effusion cell blocks including 60 malignant serous effusions (11 malignant pleural mesotheliomas and 49 metastatic carcinomas) and benign pleural effusions (14 cases with reactive mesothelial cells and 2 cases with atypical cells with uncertain significance) were selected for immunohistochemical analysis with L523S, calretinin, and CK5/6.
  • In addition, 16 cases that were originally diagnosed either as pleural effusions with reactive mesothelial cells (14) or atypical cells with uncertain significance (2) were also tested for KOC expression.
  • Interestingly, 3 of 16 cases exhibited various degrees of positivity for KOC, 2 of which were diagnosed as lung adenocarcinoma with a recurrence after tumor resection and 1 as malignant pleural mesothelioma.
  • [MeSH-major] Biomarkers, Tumor / analysis. Mesothelioma / diagnosis. Neoplasm Proteins / analysis. Pleural Effusion / diagnosis. Pleural Effusion, Malignant / diagnosis. RNA-Binding Proteins / analysis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Ascitic Fluid / chemistry. Calbindin 2. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Metastasis. Pericardial Effusion / chemistry. S100 Calcium Binding Protein G / analysis

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 American Cancer Society
  • (PMID = 18098206.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CALB2 protein, human; 0 / Calb2 protein, mouse; 0 / Calbindin 2; 0 / IMP3 protein, human; 0 / Neoplasm Proteins; 0 / RNA-Binding Proteins; 0 / S100 Calcium Binding Protein G
  •  go-up   go-down


50. Roncella S, Ferro P, Bacigalupo B, Dessanti P, Pronzato P, Franceschini MC, Pratticò L, Carletti AM, Canessa PA, Fontana V, Fais F, Pistillo MP, Fedeli F: Assessment of RT-PCR detection of human mammaglobin for the diagnosis of breast cancer derived pleural effusions. Diagn Mol Pathol; 2008 Mar;17(1):28-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of RT-PCR detection of human mammaglobin for the diagnosis of breast cancer derived pleural effusions.
  • The present study investigates the diagnostic significance of human mammaglobin (hMAM) mRNA expression in pleural effusions (PE) from breast cancer (BC) patients.
  • Two hundred and fifty PE samples, including 32 from patients who had diagnosis of BC, 116 from patients with other cancers, and 102 from patients with benign diseases, were subjected to nested reverse-transcription polymerase chain reaction (RT-PCR) for hMAM, and the results were compared with conventional cytology. hMAM was found expressed in 76/250 (30.4%) total PE and in 23/28 (sensitivity of 82.1%) of the PE subgroup owing to metastasis from BC.
  • The specificity for hMAM detection method was 75.7%, whereas accuracy, positive predictive value, and negative predictive value were 76.4%, 30.3%, and 97.1%, respectively. hMAM was also detected in 46/116 (39.6%) PE specimens from other types of cancer and in 7/102 (6.8%) from benign diseases.
  • [MeSH-major] Breast Neoplasms / diagnosis. Carcinoma / diagnosis. Neoplasm Proteins / analysis. Pleural Effusion, Malignant / diagnosis. Reverse Transcriptase Polymerase Chain Reaction. Uteroglobin / analysis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Gene Expression Regulation, Neoplastic. Humans. Mammaglobin A. Middle Aged. RNA, Messenger / metabolism. Sensitivity and Specificity. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18303409.001).
  • [ISSN] 1052-9551
  • [Journal-full-title] Diagnostic molecular pathology : the American journal of surgical pathology, part B
  • [ISO-abbreviation] Diagn. Mol. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Mammaglobin A; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / SCGB2A2 protein, human; 9060-09-7 / Uteroglobin
  •  go-up   go-down


51. Warth A, Herpel E, Schmähl A, Hoffmann H, Herth FJ, Schirmacher P, Dienemann H, Schnabel PA: Mediastinal angiomyolipomas in a male patient affected by tuberous sclerosis. Eur Respir J; 2008 Mar;31(3):678-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Classical angiomyolipomas are benign tumours composed of various tissues, including components of fat, abnormal blood vessels and smooth muscle cells.
  • The present study reports a male patient affected by TSC with intermittent, massive chylous pleural effusions, who developed recurrent mediastinal angiomyolipomas.
  • Besides lymphangioleiomyomatosis, this differential diagnosis has to be taken into account in the case of chylous pleural effusions and mediastinal masses in tuberous sclerosis complex patients.
  • [MeSH-major] Angiomyolipoma / complications. Dyspnea / etiology. Mediastinal Neoplasms / complications. Neoplasm Recurrence, Local / complications. Tuberous Sclerosis / complications
  • [MeSH-minor] Child. Child, Preschool. Humans. Male. Pleural Effusion, Malignant / etiology


52. Paiva Nunes A, Mendes I, Godinho T, Lourenço I, Jordão A, Gorjão Clara J: [Solitary fibrous tumor of the pleura]. Rev Port Cir Cardiotorac Vasc; 2007 Oct-Dec;14(4):203-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Solitary fibrous tumor of the pleura].
  • [Transliterated title] Tumor fibroso solitário da pleura.
  • Solitary fibrous tumors of the pleura are rare tumors originating from the mesenchymal cells of the submesothelial tissue of the pleura.
  • In half of the cases, the neoplasm presents as an asymptomatic mass, often with quite large dimensions.
  • It is a benign tumor in 80% of the cases and even when considered malignant has a good prognosis if totally removed.
  • We present the case of a 78-year-old female, who was evaluated for lower respiratory infection, in whom the diagnosis of Giant Solitary Fibrous Tumor of the Pleura was made.
  • [MeSH-major] Solitary Fibrous Tumor, Pleural

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18408817.001).
  • [ISSN] 0873-7215
  • [Journal-full-title] Revista portuguesa de cirurgia cardio-torácica e vascular : órgão oficial da Sociedade Portuguesa de Cirurgia Cardio-Torácica e Vascular
  • [ISO-abbreviation] Rev Port Cir Cardiotorac Vasc
  • [Language] por
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Portugal
  •  go-up   go-down


53. Bhalla R, Siddiqui MT, Mandich D, Cartun RW, Fiel-Gan MD, Nassar A, Mandavilli SR: Diagnostic utility of D2-40 and podoplanin in effusion cell blocks. Diagn Cytopathol; 2007 Jun;35(6):342-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A total of 40 cell blocks of effusion fluids including cases of epithelioid mesotheliomas, metastatic carcinomas and benign cases with reactive mesothelial cells were selected.
  • [MeSH-major] Antibodies, Neoplasm. Mesothelioma / diagnosis. Pleural Effusion, Malignant / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Humans. Immunohistochemistry

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17497664.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Neoplasm
  •  go-up   go-down


54. Bugalho A, Oliveira A, Semedo J, Lourenço I, Carreiro L: Argon-plasma treatment in benign metastasizing leiomyoma of the lung: a case report. Rev Port Pneumol; 2010 Nov-Dec;16(6):921-3; discussion 925
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Argon-plasma treatment in benign metastasizing leiomyoma of the lung: a case report.
  • Benign metastasizing leiomyomas of the lung are rare smooth muscle cells tumours.
  • Chest computed tomography revealed a left endobronchial mass, multiple parenchyma nodules and a pleural effusion.
  • Bronchial biopsy histological features were consistent with benign metastasizing leiomyoma.
  • [MeSH-minor] Female. Humans. Middle Aged. Neoplasm Metastasis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21067700.001).
  • [ISSN] 2172-6825
  • [Journal-full-title] Revista portuguesa de pneumologia
  • [ISO-abbreviation] Rev Port Pneumol
  • [Language] eng; por
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Portugal
  •  go-up   go-down


55. Pass HI, Wali A, Tang N, Ivanova A, Ivanov S, Harbut M, Carbone M, Allard J: Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions. Ann Thorac Surg; 2008 Jan;85(1):265-72; discussion 272
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions.
  • BACKGROUND: Soluble mesothelin-related peptide (SMRP) is a potential marker for malignant pleural mesothelioma (MPM), which may be useful for screening high-risk asbestos-exposed individuals.
  • METHODS: We evaluated SMRP in serum from MPM patients (n = 90), lung cancer patients (n = 170), age and tobacco-matched asbestos-exposed individuals (n = 66), and in MPM pleural effusions (n = 45), benign effusions (n = 30), and non-MPM effusions (n = 20) using the MesoMark enzyme-linked immunosorbent assay kit (Fujirebio Diagnostics, Malvern, PA).
  • The MPM pleural effusion SMRP was significantly higher than benign or other non-MPM pleural effusions (65.57 +/- 11.33 nM vs 27.46 +/- 11.25 nM [p = 0.003] and 18.99 +/- 7.48 nM [p = 0.044], respectively).
  • CONCLUSIONS: These data support SMRP as a promising marker for MPM in both serum and pleural effusion fluid, and justify prospective screening studies of SMRP in combination with other markers for screening of asbestos-exposed cohorts.
  • [MeSH-major] Biomarkers, Tumor / blood. Membrane Glycoproteins / blood. Mesothelioma / blood. Pleural Effusion, Malignant / blood. Pleural Neoplasms / blood
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Analysis of Variance. Area Under Curve. Asbestosis / blood. Asbestosis / complications. Asbestosis / mortality. Asbestosis / pathology. Case-Control Studies. Female. GPI-Linked Proteins. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging. Prognosis. ROC Curve. Retrospective Studies. Risk Assessment. Sensitivity and Specificity. Survival Analysis

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18154821.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / mesothelin
  •  go-up   go-down


56. Ouadnouni Y, Bouchikh M, Bekarsabein S, Achir A, Smahi M, Msougar Y, Mahassini N, Benosman A: Endobronchial lipoma a rare cause of pleural empyema: a case report. Cases J; 2009;2:6377
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endobronchial lipoma a rare cause of pleural empyema: a case report.
  • Benign neoplasm of the endobronchial tree is quite rare, while endobronchial lipoma is extremely rare.
  • The irreversible pulmonary damage is due to progressive bronchial obstruction; even so, pleural empyema is exceptionally encountered in a case of endobronchial lipoma.
  • The chest computed tomography showed cystic bronchiectasis with pleural effusion, Flexible bronchoscopy revealed a round tumor on the left main bronchus.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Bronconeumol. 2005 Mar;41(3):172-4 [15766470.001]
  • [Cites] Neth J Med. 1997 Oct;51(4):143-5 [9446925.001]
  • [Cites] Chest. 2003 Jan;123(1):293-6 [12527636.001]
  • [Cites] Nouv Presse Med. 1981 Jan 24;10(3):177 [7220324.001]
  • [Cites] Rofo. 1982 May;136(5):595-6 [6212510.001]
  • (PMID = 19829798.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2740244
  •  go-up   go-down


57. Balduyck B, Lauwers P, Govaert K, Hendriks J, De Maeseneer M, Van Schil P: Solitary fibrous tumor of the pleura with associated hypoglycemia: Doege-Potter syndrome: a case report. J Thorac Oncol; 2006 Jul;1(6):588-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary fibrous tumor of the pleura with associated hypoglycemia: Doege-Potter syndrome: a case report.
  • Tumor-associated hypoglycemia as a paraneoplastic phenomenon is a well-known entity and is referred to as Doege-Potter syndrome.
  • All investigations proved to be normal, except for a chest x-ray, which showed a large pleural mass.
  • On transthoracic puncture, a tumor of pleural origin was diagnosed.
  • This tumor, presenting as a large, well-circumscribed encapsulated mass, was removed by thoracotomy.
  • On pathologic examination, the diagnosis of a solitary fibrous tumor with benign characteristics was made.
  • Solitary fibrous tumors are localized tumors of the pleura with an unpredictable behavior.
  • [MeSH-major] Neoplasms, Fibrous Tissue / pathology. Neoplasms, Fibrous Tissue / surgery. Pleural Neoplasms / pathology. Pleural Neoplasms / surgery. Pneumonectomy / methods
  • [MeSH-minor] Aged. Biopsy, Needle. Bronchoscopy. Follow-Up Studies. Humans. Immunohistochemistry. Male. Neoplasm Staging. Radiography, Thoracic. Thoracotomy / methods. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Potter syndrome.
  • Genetic Alliance. consumer health - Hypoglycemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17409923.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Steinert HC: PET in lung cancer. Chang Gung Med J; 2005 May;28(5):296-305
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Accurate tumor staging is essential for choosing the appropriate treatment strategy in patients with lung cancer.
  • It has already been shown that FDG-PET is highly accurate in classifying lung nodules as benign or malignant.
  • PET-CT is superior in diagnostic accuracy for T staging and differentiation between tumor and peritumoral atelectasis.
  • A very high accuracy of FDG-PET in distinguishing recurrent disease from benign treatment effects has been shown.
  • [MeSH-minor] Carcinoma, Non-Small-Cell Lung / radionuclide imaging. Carcinoma, Small Cell / radionuclide imaging. Fluorodeoxyglucose F18. Humans. Mesothelioma / radionuclide imaging. Neoplasm Recurrence, Local / radionuclide imaging. Neoplasm Staging. Pleural Neoplasms / radionuclide imaging. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16086544.001).
  • [ISSN] 2072-0939
  • [Journal-full-title] Chang Gung medical journal
  • [ISO-abbreviation] Chang Gung Med J
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] China (Republic : 1949- )
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Number-of-references] 29
  •  go-up   go-down


59. Li G, Passebosc-Faure K, Feng G, Lambert C, Cottier M, Gentil-Perret A, Fournel P, Pérol M, Genin C: MN/CA9: a potential gene marker for detection of malignant cells in effusions. Biomarkers; 2007 Mar-Apr;12(2):214-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The presence of malignant cells in effusions has implications in diagnosis, tumour staging and prognosis.
  • The present study was to evaluate MN/CA9 as a new molecular marker for the detection of cancer cells in pleural effusions.
  • Seventy-one pleural effusions including 59 malignant effusions from patients with cancer, and 12 patients with benign diseases as a control, were subjected to RT-PCR for detection of MN/CA9 gene expression.
  • MN/CA9 gene expression was detected in 53/59 (89.8%) pleural effusions from cancer patients (15/16 for breast cancers, 10/11 for lung cancers, 4/4 for ovary cancers, 2/3 for colon-rectal cancers, 5/6 for cancers of unknown site, 7/8 for mesothelioma and 10/11 for other cancers).
  • [MeSH-major] Antigens, Neoplasm / analysis. Carbonic Anhydrases / analysis. Pleural Effusion, Malignant / pathology
  • [MeSH-minor] Biomarkers, Tumor / analysis. Case-Control Studies. Gene Expression. Humans. Neoplasm Proteins / analysis. Reverse Transcriptase Polymerase Chain Reaction. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17536770.001).
  • [ISSN] 1354-750X
  • [Journal-full-title] Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals
  • [ISO-abbreviation] Biomarkers
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; EC 4.2.1.1 / CA9 protein, human; EC 4.2.1.1 / Carbonic Anhydrases
  •  go-up   go-down


60. Mavi A, Basu S, Cermik TF, Urhan M, Bathaii M, Thiruvenkatasamy D, Houseni M, Dadparvar S, Alavi A: Potential of dual time point FDG-PET imaging in differentiating malignant from benign pleural disease. Mol Imaging Biol; 2009 Sep-Oct;11(5):369-78
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Potential of dual time point FDG-PET imaging in differentiating malignant from benign pleural disease.
  • AIM: The aim of this study was to assess the utility of dual time point 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) imaging in differentiating benign from malignant pleural disease.
  • METHODS: Fifty-five consecutive patients of suspected malignant pleural mesothelioma (MPM) and recurrence of MPM who were referred for the evaluation underwent two sequential 18F-FDG-PET scans (dual time point imaging).
  • Patients were divided into three principal groups (A = newly diagnosed MPM, B = recurrent MPM, and C = benign pleural disease).
  • The PET studies demonstrated 229 malignant pleural lesions in these patients.
  • The remaining 11 patients were proven to have benign pleural disease.
  • The mean +/- SD of the SUV(max1), SUV(max2), and Delta%SUV(max) in patients with both newly diagnosed and recurrent MPM were significantly higher than those of benign pleural disease group (p < 0.0001).
  • For each patient, the most intense (hottest) lesion's SUV(max1), SUV(max2), and Delta%SUV(max) were also compared among the aforementioned groups, and these results again confirmed that MPM lesions had significantly higher values than those of benign pleural lesions (p < 0.0001).
  • CONCLUSIONS: There is an increasing uptake of (18)F-FDG over time in pleural malignancies, whereas the uptake in benign pleural disease generally stays stable or decreases over time.
  • Therefore, dual time point imaging appears to be an effective approach in differentiating benign from malignant pleural disease, which increases the sensitivity and is also helpful in guiding the biopsy site for a successful diagnosis.
  • [MeSH-major] Fluorodeoxyglucose F18. Pleural Diseases / diagnostic imaging. Pleural Neoplasms / diagnostic imaging. Positron-Emission Tomography / methods. Radiopharmaceuticals
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans. Male. Mesothelioma / diagnosis. Mesothelioma / diagnostic imaging. Mesothelioma / metabolism. Mesothelioma / pathology. Middle Aged. Neoplasm Recurrence, Local / diagnostic imaging. Neoplasm Recurrence, Local / metabolism. Neoplasm Recurrence, Local / pathology. Time Factors

  • MedlinePlus Health Information. consumer health - Pleural Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Mol Imaging Biol. 2009 Sep-Oct;11(5):294-5 [19319607.001]
  • [Cites] Chest. 1995 Jun;107(6 Suppl):345S-350S [7781416.001]
  • [Cites] Mayo Clin Proc. 1988 Dec;63(12):1234-44 [3059081.001]
  • [Cites] J Nucl Med. 1999 Aug;40(8):1241-5 [10450672.001]
  • [Cites] Eur J Nucl Med. 1999 Oct;26(10 ):1345-8 [10541835.001]
  • [Cites] Eur J Nucl Med. 1999 Jan;26(1):22-30 [9933658.001]
  • [Cites] Chest. 1995 Oct;108(4):1122-8 [7555126.001]
  • [Cites] J Thorac Cardiovasc Surg. 2000 Jul;120(1):128-33 [10884665.001]
  • [Cites] Chest. 1995 Jun;107(6 Suppl):332S-344S [7781415.001]
  • [Cites] Chest. 1987 Jun;91(6):817-22 [3581930.001]
  • [Cites] Eur J Cardiothorac Surg. 2000 Apr;17 (4):377-83 [10773558.001]
  • [Cites] Cancer Biother Radiopharm. 2004 Apr;19(2):149-54 [15186594.001]
  • [Cites] J Comput Assist Tomogr. 1995 May-Jun;19(3):370-4 [7790544.001]
  • [Cites] Ann Thorac Surg. 1999 Nov;68(5):1799-804 [10585061.001]
  • [Cites] J Nucl Med. 2002 Jul;43(7):871-5 [12097455.001]
  • [Cites] Radiology. 1993 Aug;188(2):487-90 [8327702.001]
  • [Cites] Mol Imaging Biol. 2008 Jan-Feb;10(1):62-6 [18000713.001]
  • [Cites] Eur J Nucl Med. 1998 Jun;25(6):659-61 [9722421.001]
  • [Cites] J Thorac Cardiovasc Surg. 1988 Jul;96(1):171-7 [3386291.001]
  • [Cites] Chest. 2002 Dec;122(6):1918-24 [12475827.001]
  • [Cites] Radiol Clin North Am. 2004 Nov;42(6):983-1001, vii [15488553.001]
  • [Cites] J Nucl Med. 2004 Jun;45(6):995-8 [15181135.001]
  • [Cites] Semin Nucl Med. 2002 Oct;32(4):293-321 [12524653.001]
  • [Cites] Am J Epidemiol. 2004 Jan 15;159(2):107-12 [14718210.001]
  • [Cites] AJR Am J Roentgenol. 1996 Apr;166(4):963-8 [8610582.001]
  • [Cites] AJR Am J Roentgenol. 2000 Jul;175(1):245-9 [10882281.001]
  • [Cites] Radiol Clin North Am. 2005 Jan;43(1):1-21, ix [15693644.001]
  • [Cites] J Nucl Med. 1994 Aug;35(8):1308-12 [8046485.001]
  • [Cites] Radiol Med. 1992 Jul-Aug;84(1-2):43-7 [1509143.001]
  • [Cites] Lung Cancer. 2004 Aug;45 Suppl 1:S73-6 [15261438.001]
  • [Cites] J Nucl Med. 2006 Sep;47(9):1440-6 [16954551.001]
  • [Cites] Cancer. 2000 Dec 15;89(12 ):2547-54 [11135214.001]
  • [Cites] Am J Epidemiol. 1997 Feb 1;145(3):211-8 [9012593.001]
  • [Cites] Thorax. 1997 Feb;52(2):187-9 [9059484.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2002 Oct;29(10 ):1317-23 [12271413.001]
  • [Cites] Ann Intern Med. 1991 Feb 15;114(4):271-6 [1987873.001]
  • [Cites] Radiology. 1993 Feb;186(2):297-309 [8421723.001]
  • [Cites] J Nucl Med. 2003 Apr;44(4):540-8 [12679397.001]
  • [Cites] Chest. 1998 Sep;114(3):713-22 [9743156.001]
  • [Cites] J Nucl Med. 2001 Sep;42(9):1412-7 [11535734.001]
  • (PMID = 19472014.001).
  • [ISSN] 1860-2002
  • [Journal-full-title] Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging
  • [ISO-abbreviation] Mol Imaging Biol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


61. Kanauchi N, Oizumi H, Honma T, Kato H, Endo M, Suzuki J, Fukaya K, Sadahiro M: Role of diffusion-weighted magnetic resonance imaging for predicting of tumor invasiveness for clinical stage IA non-small cell lung cancer. Eur J Cardiothorac Surg; 2009 Apr;35(4):706-10; discussion 710-1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of diffusion-weighted magnetic resonance imaging for predicting of tumor invasiveness for clinical stage IA non-small cell lung cancer.
  • Favorable results have been reported using this imaging system to differentiate between benign and malignant lesions in some organs, and to correlate with the degree of cell differentiation in lung cancer.
  • The purpose of this study was to assess the role of DWI for predicting tumor invasiveness of non-small cell lung cancers (NSCLC), especially for clinical stage IA patients.
  • Lung cancers that exhibited nodal, lymphovascular or pleural invasion were defined as invasive lung cancers.
  • We analyzed the associations between the pathological findings and the following preoperative clinical factors: age, gender, smoking history, preoperative CEA levels (<5.0 or >/=5.0ng/ml), preoperative tumor size, SUV max on PET/CT (<5.0 or >/=5.0) and DWI (positive or negative).
  • Multivariate analysis showed that DWI (p=0.005) was an independent predictive factor for tumor invasiveness.
  • CONCLUSION: Our results suggest that DWI might be a useful method for predicting tumor invasiveness for clinical stage IA NSCLC.
  • [MeSH-minor] Aged. Aged, 80 and over. Cell Differentiation. Diffusion Magnetic Resonance Imaging. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Predictive Value of Tests. Prognosis

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19216085.001).
  • [ISSN] 1873-734X
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


62. Fassina A, Fedeli U, Corradin M, Da Frè M, Fabbris L: Accuracy and reproducibility of pleural effusion cytology. Leg Med (Tokyo); 2008 Jan;10(1):20-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Accuracy and reproducibility of pleural effusion cytology.
  • The increasing number of Malignant Mesothelioma (MM) cases that arrive for expert examinations to court for compensation reasons in subjects exposed to asbestos, in many instances rely exclusively on cytological smears of pleural effusion.
  • We evaluated the accuracy and reproducibility of cytological pleural effusions, based on morphological criteria alone.
  • Nine pathologists and eight residents from seven institutions in north-east Italy blindly examined 45 smears of MM (17), metastases (14) and benign effusions (14), in two rounds.
  • Diagnostic accuracy, interobserver and intraobserver agreement in the distinction of benign vs malignant cases, and in the differentiation of primary from metastatic malignancies, were evaluated.
  • The distinction of benign from malignant smears resulted rather satisfactory (k=0.514), but markedly decreased in differentiation of MM from metastases (overall agreement: k=0.343), as well as when readings from residents were analyzed (k=0.132).
  • Cytology is a useful and reliable tool in the identification of malignancies, but when the distinction of primary from metastatic tumors is addressed morphological criteria alone are not sufficient for a definite diagnosis of MM and the use of cell blocks, immunohistochemistry (IHC) and molecular ancillary techniques are recommended.
  • [MeSH-major] Mesothelioma / diagnosis. Neoplasm Metastasis / diagnosis. Pleural Effusion / pathology. Pleural Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17702624.001).
  • [ISSN] 1344-6223
  • [Journal-full-title] Legal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Leg Med (Tokyo)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


63. Cagle PT, Churg A: Differential diagnosis of benign and malignant mesothelial proliferations on pleural biopsies. Arch Pathol Lab Med; 2005 Nov;129(11):1421-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential diagnosis of benign and malignant mesothelial proliferations on pleural biopsies.
  • CONTEXT: Although much of the pathology literature focuses on differential diagnosis of diffuse malignant mesothelioma from other types of cancer, the primary diagnostic challenge facing the pathologist is often whether a mesothelial proliferation on a pleural biopsy represents a malignancy or a benign reactive hyperplasia.
  • DESIGN: Based on previous medical publications, extensive personal consultations, and experience on the United States-Canadian Mesothelioma Reference Panel and the International Mesothelioma Panel, salient information was determined about interpretation of benign versus malignant mesothelial proliferations on pleural biopsies.
  • RESULTS: Differentiation of benign reactive mesothelial hyperplasia from diffuse malignant mesothelioma is often difficult.
  • Benign reactive mesothelial hyperplasia may mimic many features ordinarily associated with malignancy, and diffuse malignant mesothelioma may be cytologically bland.
  • Entrapment of benign reactive mesothelial cells within organizing pleuritis may mimic tissue invasion.
  • CONCLUSIONS: Various histologic clues favor a benign over a malignant mesothelial proliferation and vice versa.
  • When there is any doubt that a pleural biopsy represents a malignancy, we recommend a diagnosis of atypical mesothelial proliferation.
  • [MeSH-major] Epithelium / pathology. Mesothelioma / pathology. Pleura / pathology. Pleural Neoplasms / pathology
  • [MeSH-minor] Biopsy. Diagnosis, Differential. Humans. Hyperplasia / pathology. Neoplasm Invasiveness

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16253023.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 19
  •  go-up   go-down


64. Kalebi AY, Hale MJ, Wong ML, Hoffman T, Murray J: Surgically cured hypoglycemia secondary to pleural solitary fibrous tumour: case report and update review on the Doege-Potter syndrome. J Cardiothorac Surg; 2009;4:45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgically cured hypoglycemia secondary to pleural solitary fibrous tumour: case report and update review on the Doege-Potter syndrome.
  • The association of paraneoplastic hypoglycemia [Doege-Potter syndrome] and finger clubbing [Pierre-Marie-Bamberg syndrome] with pleural solitary fibrous tumour is rare.
  • We present a previously unpublished but typical example of this rare occurrence together with a detailed updated literature review of previously published cases of pleural SFT discussing the histopathology of SFT; pathophysiology of the hypoglycemia and finger clubbing; treatment and outcome of pleural SFT.
  • Less than 65 cases of pleural SFT manifesting with hypoglycemia with or without finger-clubbing have been published in the English literature.
  • The mean diameter of these tumours manifesting with hypoglycemia is 20 cm, 54% being benign while 42% were malignant.
  • [MeSH-major] Hypoglycemia / surgery. Osteoarthropathy, Secondary Hypertrophic / surgery. Paraneoplastic Syndromes / surgery. Solitary Fibrous Tumor, Pleural / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Blood Glucose / analysis. C-Peptide / analysis. Female. Humans. Insulin / analysis. Male. Middle Aged. Neoplasm Recurrence, Local. Treatment Outcome

  • Genetic Alliance. consumer health - Potter syndrome.
  • Genetic Alliance. consumer health - Hypoglycemia.
  • MedlinePlus Health Information. consumer health - Hypoglycemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 1995 Apr;26(4):440-9 [7705824.001]
  • [Cites] Obstet Gynecol. 1995 May;85(5 Pt 2):810-3 [7724120.001]
  • [Cites] Magn Reson Imaging. 1997;15(3):377-9 [9201687.001]
  • [Cites] APMIS. 1997 Jun;105(6):469-82 [9236865.001]
  • [Cites] Ann Thorac Surg. 1998 May;65(5):1461-4 [9594894.001]
  • [Cites] Diabetologia. 1998 May;41(5):589-94 [9628278.001]
  • [Cites] J Biol Chem. 1998 Jul 17;273(29):18443-51 [9660813.001]
  • [Cites] Eur J Cardiothorac Surg. 1998 Nov;14(5):453-9 [9860200.001]
  • [Cites] Eur J Cardiothorac Surg. 1999 Jan;15(1):84-6 [10077378.001]
  • [Cites] Lung Cancer. 1999 Jan;23(1):53-60 [10100146.001]
  • [Cites] Ann Thorac Surg. 1999 May;67(5):1456-9 [10355431.001]
  • [Cites] N Engl J Med. 1999 Sep 2;341(10):757-8 [10471466.001]
  • [Cites] Mt Sinai J Med. 2004 Oct;71(5):344-6 [15543436.001]
  • [Cites] Int J Dermatol. 2004 Dec;43(12):944-7 [15569027.001]
  • [Cites] Ann Thorac Surg. 2005 Jan;79(1):303-7 [15620963.001]
  • [Cites] Int J Gynecol Pathol. 2005 Jan;24(1):79-84 [15626921.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Aug 2;102(31):11047-52 [16040806.001]
  • [Cites] Clin Lung Cancer. 2005 Nov;7(3):197-201 [16354315.001]
  • [Cites] Thorac Cardiovasc Surg. 2006 Feb;54(1):65-7 [16485194.001]
  • [Cites] Intern Med. 2006;45(8):525-9 [16702745.001]
  • [Cites] J Surg Oncol. 2006 Jul 1;94(1):40-4 [16788942.001]
  • [Cites] J Assoc Physicians India. 2006 May;54:413-5 [16909744.001]
  • [Cites] J Am Coll Surg. 2006 Sep;203(3):398 [16931312.001]
  • [Cites] J Thorac Cardiovasc Surg. 2006 Sep;132(3):713-4 [16935145.001]
  • [Cites] Cancer Control. 2006 Oct;13(4):264-9 [17075563.001]
  • [Cites] Int J Clin Oncol. 2006 Dec;11(6):478-81 [17180519.001]
  • [Cites] J Thorac Oncol. 2006 Jul;1(6):588-90 [17409923.001]
  • [Cites] Eur J Cardiothorac Surg. 2007 May;31(5):955-7 [17317199.001]
  • [Cites] J Clin Endocrinol Metab. 2007 May;92(5):1600-5 [17299065.001]
  • [Cites] J Clin Endocrinol Metab. 2007 May;92(5):1616 [17483375.001]
  • [Cites] Am Surg. 2007 May;73(5):478-80 [17521003.001]
  • [Cites] Ann Thorac Surg. 2007 Jul;84(1):292-4 [17588442.001]
  • [Cites] Eur J Cardiothorac Surg. 2007 Sep;32(3):403-8 [17646108.001]
  • [Cites] J Am Acad Dermatol. 2007 Nov;57(5 Suppl):S106-10 [17938018.001]
  • [Cites] Pathol Int. 2007 Dec;57(12):791-3 [17988280.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2007;14(6):595-9 [18040628.001]
  • [Cites] Respiration. 2008;75(1):109-12 [17259691.001]
  • [Cites] J BUON. 2008 Jan-Mar;13(1):117-21 [18404798.001]
  • [Cites] Spine (Phila Pa 1976). 2008 May 20;33(12):E397-9 [18496336.001]
  • [Cites] Int J Surg. 2008 Aug;6(4):298-301 [18579460.001]
  • [Cites] Am J Surg Pathol. 2008 Nov;32(11):1627-42 [18753943.001]
  • [Cites] Endocr J. 2008 Oct;55(5):905-11 [18552458.001]
  • [Cites] J Thorac Cardiovasc Surg. 2000 Jan;119(1):185-7 [10612786.001]
  • [Cites] J Endocrinol. 2000 May;165(2):253-60 [10810289.001]
  • [Cites] Exp Clin Endocrinol Diabetes. 2000;108(8):515-8 [11149628.001]
  • [Cites] J Cardiovasc Surg (Torino). 2000 Oct;41(5):781-4 [11149649.001]
  • [Cites] Ann Thorac Surg. 2000 Dec;70(6):1808-12 [11156076.001]
  • [Cites] Anticancer Res. 2000 Nov-Dec;20(6C):4701-6 [11205204.001]
  • [Cites] Eur J Cardiothorac Surg. 2001 Feb;19(2):185-9 [11167110.001]
  • [Cites] J Korean Med Sci. 2001 Apr;16(2):220-4 [11306751.001]
  • [Cites] Intern Med. 2001 Apr;40(4):341-4 [11334396.001]
  • [Cites] Cancer. 2002 Feb 15;94(4):1057-68 [11920476.001]
  • [Cites] Eur J Cardiothorac Surg. 2002 Jun;21(6):1087-93 [12048090.001]
  • [Cites] Clin Orthop Relat Res. 2003 Jun;(411):236-44 [12782880.001]
  • [Cites] Med Oncol. 2003;20(4):403-8 [14716039.001]
  • [Cites] Arch Pathol Lab Med. 2004 Apr;128(4):460-2 [15043457.001]
  • [Cites] J Natl Med Assoc. 2004 May;96(5):659-62, 664 [15160981.001]
  • [Cites] Cancer. 1981 Jun 1;47(11):2678-89 [7260861.001]
  • [Cites] N Engl J Med. 1982 May 13;306(19):1178-9 [7040961.001]
  • [Cites] Aust N Z J Med. 1982 Feb;12(1):70-2 [7044359.001]
  • [Cites] Arch Intern Med. 1983 Aug;143(8):1608-10 [6870444.001]
  • [Cites] Chest. 1986 Feb;89(2):289-90 [3943390.001]
  • [Cites] N Engl J Med. 1988 Dec 1;319(22):1434-40 [3185662.001]
  • [Cites] Am J Surg Pathol. 1989 Aug;13(8):640-58 [2665534.001]
  • [Cites] South Med J. 1990 Jun;83(6):690-4 [2162571.001]
  • [Cites] Thorax. 1991 Dec;46(12):932-3 [1792644.001]
  • [Cites] J Clin Endocrinol Metab. 1992 Jul;75(1):110-5 [1618998.001]
  • [Cites] J Ky Med Assoc. 1992 Nov;90(11):557-60 [1474302.001]
  • [Cites] Chest. 1994 Sep;106(3):965-7 [8082393.001]
  • (PMID = 19689813.001).
  • [ISSN] 1749-8090
  • [Journal-full-title] Journal of cardiothoracic surgery
  • [ISO-abbreviation] J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Blood Glucose; 0 / C-Peptide; 0 / Insulin
  • [Number-of-references] 78
  • [Other-IDs] NLM/ PMC2739517
  •  go-up   go-down


65. Shibata K, Yuki D, Sakata K: Multiple calcifying fibrous pseudotumors disseminated in the pleura. Ann Thorac Surg; 2008 Feb;85(2):e3-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple calcifying fibrous pseudotumors disseminated in the pleura.
  • Calcifying fibrous pseudotumor is an extremely rare benign lesion that develops in the pleura.
  • We describe a case of multiple lesions in the pleura.
  • The diagnosis was established by percutaneous needle biopsy.
  • The largest tumor was hanging down from the parietal pleura, and additional small nodules were disseminated throughout the pleural cavity.
  • [MeSH-major] Calcinosis / pathology. Pleural Diseases / pathology. Thoracic Surgery, Video-Assisted / methods
  • [MeSH-minor] Biopsy, Needle. Female. Follow-Up Studies. Granuloma, Plasma Cell / pathology. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging. Risk Assessment. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pleural Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18222223.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 9
  •  go-up   go-down


66. Okagawa T, Uchida T, Suyama M: Thymoma with spontaneous regression and disappearance of pleural effusion. Gen Thorac Cardiovasc Surg; 2007 Dec;55(12):515-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thymoma with spontaneous regression and disappearance of pleural effusion.
  • Chest radiography and computed tomography (CT) on admission showed an anterior mediastinal tumor with left pleural effusion, which was diagnosed as an inoperable malignant mediastinal tumor.
  • However, 3 weeks after admission CT showed that the tumor was diminishing and the pleural effusion had disappeared without any treatment.
  • CT-guided needle biopsy was performed, but diagnosis was impossible because most of the specimen was necrotic.
  • The intraoperative finding showed that the tumor was round, well mobilized, and did not invade adjacent structures.
  • It was then assumed to be a benign teratoma that had been ruptured into the thoracic cavity.
  • Two months later, total thymectomy was performed through a median sternotomy because the tumor was pathologically diagnosed as a thymoma.
  • [MeSH-major] Mediastinal Neoplasms / pathology. Neoplasm Regression, Spontaneous. Pleural Effusion, Malignant / etiology. Thymoma / pathology. Thyroid Neoplasms / pathology
  • [MeSH-minor] Adult. Biopsy, Needle. Cautery. Diagnosis, Differential. Female. Humans. Magnetic Resonance Imaging. Necrosis. Thoracic Surgery, Video-Assisted. Thoracotomy. Thymectomy. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2001 Aug;25(8):1086-90 [11474295.001]
  • [Cites] Am J Clin Pathol. 2004 Jun;121(6):867-71 [15198359.001]
  • [Cites] Histopathology. 1994 Sep;25(3):289-91 [7821901.001]
  • (PMID = 18066646.001).
  • [ISSN] 1863-6705
  • [Journal-full-title] General thoracic and cardiovascular surgery
  • [ISO-abbreviation] Gen Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


67. Wu LY, Liu BR, Lu J, Ling MD, Chen J, Li P, Jiang Y: [Significance of FCM-DNA ploidy pattern, AgNOR counting, hTERT and PCNA expression in differentiating malignant from benign serous effusion]. Ai Zheng; 2007 Feb;26(2):178-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Significance of FCM-DNA ploidy pattern, AgNOR counting, hTERT and PCNA expression in differentiating malignant from benign serous effusion].
  • BACKGROUND & OBJECTIVE: Differentiating malignant from benign serous effusion is still a difficulty in clinic at present.
  • This study was to explore the clinical value of flow cytometry (FCM)-DNA ploidy, argyrophilic nucleolar organizer region (AgNOR) staining, human telomerase reverse transcriptase (hTERT) and proliferating cell nuclear antigen (PCNA) expression in differentiating malignant from benign serous effusion.
  • RESULTS: There were significant differences in FCM-DNA ploidy, AgNOR staining, hTERT and PCNA expression between malignant and benign serous effusion.
  • [MeSH-major] Aneuploidy. Nucleolus Organizer Region / pathology. Pleural Effusion / diagnosis. Pleural Effusion, Malignant / diagnosis. Proliferating Cell Nuclear Antigen / metabolism. Telomerase / metabolism
  • [MeSH-minor] DNA, Neoplasm / genetics. Diagnosis, Differential. Female. Flow Cytometry. Humans. Male. Middle Aged. Neoplasms / complications. Silver Staining

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17298749.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Proliferating Cell Nuclear Antigen; EC 2.7.7.49 / TERT protein, human; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


68. Shibata H, Nomori H, Uno K, Iyama K, Tomiyoshi K, Nakashima R, Sakaguchi K, Goya T, Takanami I, Koizumi K, Suzuki T, Kaji M, Horio H: 11C-acetate for positron emission tomography imaging of clinical stage IA lung adenocarcinoma: comparison with 18F-fluorodeoxyglucose for imaging and evaluation of tumor aggressiveness. Ann Nucl Med; 2009 Sep;23(7):609-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 11C-acetate for positron emission tomography imaging of clinical stage IA lung adenocarcinoma: comparison with 18F-fluorodeoxyglucose for imaging and evaluation of tumor aggressiveness.
  • BACKGROUND: To determine the usefulness of positron emission tomography (PET) with (11)C-acetate (AC) for imaging lung adenocarcinoma and evaluating its tumor aggressiveness, AC- and (18)F-fluorodeoxyglucose (FDG)-PET were compared.
  • METHODS: One hundred and sixty-nine adenocarcinomas with clinical stage IA and 53 benign nodules were examined by both AC- and FDG-PET before surgery.
  • The sensitivity and specificity for discriminating benign/adenocarcinoma were compared between AC- and FDG-PET.
  • The AC and FDG uptakes were examined to determine the relationship with tumor aggressiveness, i.e., pathological tumor stage, lymphatic, vascular, or pleural involvement, and proliferative activity determined by Ki-67 staining score.
  • While FDG uptakes were significantly higher in tumors with pathological advanced stages or those with lymphatic, vascular and/or pleural involvements than in tumors with pathological stage IA or those without these tumor involvements (p = 0.04 to p < 0.001), AC uptake did not show significant differences between the respective sub-groups except according to the tumor stage.
  • CONCLUSIONS: While AC-PET can image BAC and W/D adenocarcinoma with a higher sensitivity than FDG-PET, it cannot evaluate tumor aggressiveness of clinical stage IA lung adenocarcinoma as well as FDG-PET.
  • [MeSH-minor] Humans. Neoplasm Staging. Positron-Emission Tomography. ROC Curve. Tomography, X-Ray Computed. Tumor Burden

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CARBON .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19562438.001).
  • [ISSN] 1864-6433
  • [Journal-full-title] Annals of nuclear medicine
  • [ISO-abbreviation] Ann Nucl Med
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Acetates; 0 / carbon-11 acetate; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 7440-44-0 / Carbon
  •  go-up   go-down


69. Liang QL, Shi HZ, Qin XJ, Liang XD, Jiang J, Yang HB: Diagnostic accuracy of tumour markers for malignant pleural effusion: a meta-analysis. Thorax; 2008 Jan;63(1):35-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic accuracy of tumour markers for malignant pleural effusion: a meta-analysis.
  • BACKGROUND: The role of tumour markers such as carbohydrate antigen (CA) 125, CA 15-3, CA 19-9 and CYFRA 21-1 (a fragment of cytokeratin 19) in differentiating malignant pleural effusions (MPE) from benign effusions is not yet clear.
  • METHODS: After a systematic review of English language studies, sensitivity, specificity and other measures of accuracy of pleural concentrations of CA 125, CA 15-3, CA 19-9 and CYFRA 21-1 or their combinations in the diagnosis of MPE were pooled using random effects models.
  • The summary estimates of the sensitivity and specificity of these tumour markers were as follows: CA 125, 0.48/0.85; CA 15-3, 0.51/0.96; CA 19-9, 0.25/0.96; CYFRA 21-1, 0.55/0.91 for diagnosing MPE.
  • The estimated summary receiver operating characteristic curves showed that the performance of pleural CA 125 and CA 19-9 measurement in the diagnosis of MPE was limited, whereas that of CA 15-3 and CYFRA 21-1 was better.
  • When two or more of the above four tumour markers were combined, or combined with carcinoembryonic antigen, the sensitivity and specificity were all increased to different extents.
  • CONCLUSIONS: The current evidence does not recommend using one tumour marker alone for the diagnosis of MPE, but the combination of two or more tumour markers seems to be more sensitive.
  • The results of tumour marker assays should be interpreted in parallel with clinical findings and the results of conventional tests.
  • [MeSH-major] Antigens, Neoplasm / blood. CA-125 Antigen / blood. CA-19-9 Antigen / blood. Keratins / blood. Mucin-1 / blood. Pleural Effusion, Malignant / diagnosis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17573438.001).
  • [ISSN] 1468-3296
  • [Journal-full-title] Thorax
  • [ISO-abbreviation] Thorax
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / CA-125 Antigen; 0 / CA-19-9 Antigen; 0 / Keratin-19; 0 / Mucin-1; 0 / antigen CYFRA21.1; 68238-35-7 / Keratins
  • [Number-of-references] 27
  •  go-up   go-down


70. Németh T, Furák J, Wolfárd A, Géczi T, Tiszlavicz L, Lázár G: [Surgical treatment of primary pleural tumours in our department]. Magy Seb; 2010 Apr;63(2):67-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical treatment of primary pleural tumours in our department].
  • AIM: The authors analyzed the results and outcome of surgical treatment of primary pleural tumors in patients treated in the last 11 years.
  • METHODS: 31 operations were performed for primary pleural tumors in 25 patients (17 males, 8 females).
  • The tumors were classified into the following groups: benign local fibrous tumors (benign LFTP; n = 15), recurrent malignant fibrous tumors (recurrent malignant LFTP; n = 2) and malignant mesotheliomas (MPM; n = 12).
  • Complete resections of benign LFTPs were performed, with additional resection of the chest wall and lobectomy in two cases.
  • In four cases, after the biopsy, two pleurectomies and decortications (P/D) and two pleuropneumonectomies (PPN)/extra-pleural pneumonectomies (EPP) were carried out.
  • [MeSH-major] Pleural Neoplasms / surgery
  • [MeSH-minor] Aged. Biopsy. Carcinoma / surgery. Female. Humans. Hungary. Male. Mesothelioma / surgery. Middle Aged. Neoplasm Staging. Pleurodesis. Pneumonectomy. Retrospective Studies. Sarcoma / surgery. Thoracic Surgery, Video-Assisted. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20400397.001).
  • [ISSN] 0025-0295
  • [Journal-full-title] Magyar sebészet
  • [ISO-abbreviation] Magy Seb
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  •  go-up   go-down


71. Zhang KH, Cao F, Fu QB, Zhu JQ, Chen J, Lv NH: Detection of mRNAs of GA733 genes by RT-PCR in exfoliated cells of pleural and peritoneal effusions and its clinical values. Intern Med; 2007;46(18):1489-94
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of mRNAs of GA733 genes by RT-PCR in exfoliated cells of pleural and peritoneal effusions and its clinical values.
  • OBJECTIVE: To evaluate the diagnostic values of the detection of mRNAs of GA733 gene family in exfoliated cells of pleural and peritoneal effusions.
  • METHODS: Sixty specimens of pleural and peritoneal fluids from 60 patients were collected.
  • Patients Sixty patients with pleural or peritoneal effusions, from May 2003 and August 2004, aged 23-85 (average 56.5 years).
  • RESULTS: GA733-1 and GA733-2 mRNA were positive in 5 (13.9%) and 27 (75.0%) of 36 malignant specimens, and in 1 and 7 of 11 cause-unknown specimens, respectively, but both of them were negative in all 13 benign specimens, and the difference of GA733-2 mRNA positive rates among the three groups was significant (P<0.005), but that of GA733-1 mRNA was not (P>0.05).
  • Sensitivity, specificity and accuracy of detection for GA733-2 mRNA for diagnosis of malignant effusions were 75.0%, 100% and 81.6%, respectively.
  • CONCLUSIONS: The detection of GA733-2 mRNA by qualitative RT-PCR is sensitive and highly specific for the diagnosis of malignant pleural and peritoneal effusions, while the diagnostic value of GA733-1 mRNA needs to be further investigated.
  • [MeSH-major] Antigens, Neoplasm / genetics. Ascitic Fluid / metabolism. Ascitic Fluid / pathology. Biomarkers, Tumor / genetics. Cell Adhesion Molecules / genetics. Pleural Effusion, Malignant / diagnosis. Pleural Effusion, Malignant / genetics. RNA, Messenger / isolation & purification. Reverse Transcriptase Polymerase Chain Reaction / methods

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17878632.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Cell Adhesion Molecules; 0 / RNA, Messenger; 0 / tumor-associated antigen GA733
  •  go-up   go-down


72. Robinson LA: Solitary fibrous tumor of the pleura. Cancer Control; 2006 Oct;13(4):264-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary fibrous tumor of the pleura.
  • BACKGROUND: The solitary fibrous tumor of the pleura (SFTP) is a rare primary tumor arising from mesenchymal cells in the areolar tissue subjacent to the mesothelial-lined pleura.
  • The tumor appears to be unrelated to malignant pleural mesothelioma, the most common primary tumor of the pleura.
  • METHODS: In just over half of these cases, the neoplasm presents as an asymptomatic mass, is often quite large, and is benign in 78% to 88% of patients.
  • The initial evaluation and diagnosis, tumor classification, surgical treatment, results of therapy, and long-term prognosis are reviewed, based on a selective review of the literature from MEDLINE beginning 1980.
  • RESULTS: Complete en bloc surgical resection is the preferred treatment of benign and malignant varieties of the tumor.
  • The pedunculated tumors attached to the visceral pleura can be effectively treated with a wedge resection of lung.
  • CONCLUSIONS: Benign SFTP has a high cure rate and an 8% local recurrence rate that is usually amenable to curative re-excision.
  • The majority of patients with recurrent disease die of the tumor within 2 years.
  • [MeSH-major] Neoplasms, Fibrous Tissue / diagnosis. Neoplasms, Fibrous Tissue / therapy. Pleural Neoplasms / diagnosis. Pleural Neoplasms / therapy
  • [MeSH-minor] Diagnosis, Differential. Humans. Incidence. Neoadjuvant Therapy. Thoracic Surgical Procedures. Tomography, X-Ray Computed. United States / epidemiology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17075563.001).
  • [ISSN] 1073-2748
  • [Journal-full-title] Cancer control : journal of the Moffitt Cancer Center
  • [ISO-abbreviation] Cancer Control
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 21
  •  go-up   go-down


73. Yamamuro M, Gerbaudo VH, Gill RR, Jacobson FL, Sugarbaker DJ, Hatabu H: Morphologic and functional imaging of malignant pleural mesothelioma. Eur J Radiol; 2007 Dec;64(3):356-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Morphologic and functional imaging of malignant pleural mesothelioma.
  • Malignant pleural mesothelioma (MPM) is an aggressive tumor that arises from the pleura and frequently extends to adjacent structures.
  • Major findings include nodular pleural thickening, unilateral pleural effusion, and tumor invasion of adjacent structures.
  • Because of its excellent contrast resolution, MRI is superior to CT, both in the differentiation of malignant from benign pleural disease, and in the assessment of chest wall and diaphragmatic involvement.
  • Perfusion MRI is the most promising technique for the assessment of the tumor microvasculature.
  • It has been shown that FDG-PET is useful for the differentiation of benign from malignant lesions, for staging and monitoring metabolic response to therapy against MPM, and that it has prognostic value.
  • An initial report on PET/CT imaging of MPM has shown increased accuracy of overall staging, improving the assessment of tumor resectability.
  • [MeSH-major] Diagnostic Imaging / methods. Mesothelioma / diagnosis. Pleural Neoplasms / diagnosis
  • [MeSH-minor] Humans. Magnetic Resonance Imaging / methods. Neoplasm Staging. Neovascularization, Pathologic / diagnosis. Positron-Emission Tomography / methods. Tomography, X-Ray Computed / methods


74. Seyfarth HJ, Wirtz H, Borte G, Gradistanac T, Gessner C, Hammerschmidt S: [Ultrasound guided transthoracic biopsy - safety and efficaces]. Pneumologie; 2007 Sep;61(9):563-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The biopsy of pulmonary neoplasms localized in close proximity of the thoracic wall and the histological examination of the specimens represent an important diagonstic tool in the work up of benign and malign pulmonary tumours.
  • 43 pulmonary or pleural and 3 mediastinal neoplasms were investigated.
  • The neoplasm reached the pleura in 41 cases.
  • RESULTS: The histological examination provided the diagnosis in 44 of 46 cases (95.6 %): lung cancer n = 29, other malign tumours n = 9; benign tumours n = 6).

  • MedlinePlus Health Information. consumer health - COPD.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17602390.001).
  • [ISSN] 1438-8790
  • [Journal-full-title] Pneumologie (Stuttgart, Germany)
  • [ISO-abbreviation] Pneumologie
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


75. Casanova Espinosa A, Cisneros Serrano C, Girón Moreno RM, Olivera MJ, Moreno Balsalobre R, Zamora García E: [Pleural empyema associated with endobronchial lipoma]. Arch Bronconeumol; 2005 Mar;41(3):172-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pleural empyema associated with endobronchial lipoma].
  • [Transliterated title] Empiema pleural asociado a lipoma endobronquial.
  • Bronchial benign tumors comprise fewer than 4% of pulmonary neoplasms.
  • Endobronchial lipoma is an extremely rare benign neoplasm accounting for only 0.1% to 0.5% of all lung tumors.
  • Clinical symptoms of lipoma depend on the location of the tumor, the severity of bronchial obstruction, and the functional and anatomical effects on the parenchyma distal to the obstruction.
  • Computed axial tomography usually reveals the adipose composition of the lipomatous tumor.
  • We report the case of an 83-year-old man diagnosed with community-acquired pneumonia that led to complications: pleural empyema caused by Haemophilus influenzae infection and atelectasis of the right middle and lower lobes secondary to a lipomatous endobronchial obstruction.
  • [MeSH-major] Bronchial Neoplasms / complications. Empyema, Pleural / etiology. Lipoma / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15766470.001).
  • [ISSN] 0300-2896
  • [Journal-full-title] Archivos de bronconeumología
  • [ISO-abbreviation] Arch. Bronconeumol.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


76. Manosca F, Schinstine M, Fetsch PA, Sorbara L, Maria Wilder A, Brosky K, Erickson D, Raffeld M, Filie AC, Abati A: Diagnostic effects of prolonged storage on fresh effusion samples. Diagn Cytopathol; 2007 Jan;35(1):6-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Specimens evaluated included four pleural (3 benign, 1 breast adenocarcinoma) and six peritoneal (2 ovarian adenocarcinomas, 1 malignant melanoma, 2 mesotheliomas, 1 atypical mesothelial) effusions.
  • [MeSH-major] Artifacts. Ascitic Fluid / pathology. Cytodiagnosis / methods. Neoplasms / diagnosis. Pleural Effusion, Malignant / diagnosis. Specimen Handling / methods
  • [MeSH-minor] Adult. Biomarkers, Tumor. DNA, Neoplasm / analysis. Female. Humans. Male. Middle Aged. Polymerase Chain Reaction. Time Factors

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17173298.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm
  •  go-up   go-down


77. Hill DA, Jarzembowski JA, Priest JR, Williams G, Schoettler P, Dehner LP: Type I pleuropulmonary blastoma: pathology and biology study of 51 cases from the international pleuropulmonary blastoma registry. Am J Surg Pathol; 2008 Feb;32(2):282-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pleuropulmonary blastoma (PPB) is a malignant neoplasm of the lung that presents in early childhood.
  • Type I PPB is a delicate multilocular cyst with variable numbers of primitive mesenchymal cells beneath a benign epithelial surface.
  • Early tumors have a subtle transition between normal developing lung and tumor, showing bland interstitial mesenchymal cells uniformly expanding the alveolar septa.
  • This phenomenon may explain the variable and sometimes sparse tumor cellularity seen in some type I PPBs.
  • Factors that control the balance between progression and regression may be important in predicting tumor behavior and determining which patients will benefit from adjuvant chemotherapy.
  • In the meantime, recognition of this lesion as a neoplasm with malignant potential rather than a developmental cystic malformation is vital so the child can receive complete excision and appropriate follow-up care.
  • [MeSH-major] Cystic Adenomatoid Malformation of Lung, Congenital / pathology. Lung Neoplasms / pathology. Pleural Neoplasms / pathology. Pulmonary Blastoma / pathology
  • [MeSH-minor] Age Factors. Child. Child, Preschool. Combined Modality Therapy. Cysts / pathology. Diagnosis, Differential. Family Health. Female. Genetic Predisposition to Disease. Humans. Infant. Infant, Newborn. International Cooperation. Male. Registries


78. Soldano AC, Meehan SA: Cutaneous solitary fibrous tumor: a report of 2 cases and review of the literature. Am J Dermatopathol; 2008 Feb;30(1):54-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous solitary fibrous tumor: a report of 2 cases and review of the literature.
  • Solitary fibrous tumor is an uncommon mesenchymal neoplasm that can arise in both pleural and extrapleural locations.
  • Composed of spindled cells intimately admixed with collagen bundles arranged in a "patternless pattern," this heterogeneous tumor can mimic a variety of benign and malignant mesenchymal neoplasms.
  • We present the histological and immunohistochemical findings of two primary cutaneous solitary fibrous tumors, discuss the differential diagnosis, and review the literature.
  • Although solitary fibrous tumors in cutaneous and subcutaneous regions are extremely rare, it should be considered in the differential diagnosis of primary spindle cell neoplasms of the skin.
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Immunohistochemistry

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18212546.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


79. Nussbaumer P, Furrer M: [The role of video-thoracoscopy in thoracic surgery]. Ther Umsch; 2005 Feb;62(2):77-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • For therapeutic procedures, VATS has also been generally accepted as the treatment for spontaneous pneumothorax, thoracic sympathectomy, treatment of loculated effusions and resection of simple mediastinal cysts and benign tumors.
  • [MeSH-minor] Aged. Carcinoma, Bronchogenic / diagnosis. Carcinoma, Bronchogenic / pathology. Carcinoma, Renal Cell. Diagnosis, Differential. Empyema, Pleural / surgery. Humans. Kidney Neoplasms. Lung / pathology. Lung / surgery. Lung Neoplasms / diagnosis. Lung Neoplasms / pathology. Lung Neoplasms / secondary. Male. Mediastinal Cyst / diagnosis. Mediastinal Cyst / surgery. Neoplasm Staging. Pleural Effusion / diagnosis. Pleural Effusion / surgery. Pneumothorax / diagnosis. Pneumothorax / surgery. Sympathectomy. Thymectomy. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15756915.001).
  • [ISSN] 0040-5930
  • [Journal-full-title] Therapeutische Umschau. Revue thérapeutique
  • [ISO-abbreviation] Ther Umsch
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 51
  •  go-up   go-down


80. Santos RS, Haddad R, Lima CE, Liu YL, Misztal M, Ferreira T, Boasquevisque CH, Luketich JD, Landreneau RJ: Patterns of recurrence and long-term survival after curative resection of localized fibrous tumors of the pleura. Clin Lung Cancer; 2005 Nov;7(3):197-201
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns of recurrence and long-term survival after curative resection of localized fibrous tumors of the pleura.
  • BACKGROUND: Localized fibrous tumors of the pleura (LFTPs) are uncommon thoracic neoplasms with variable malignant potential that were previously classified as benign presentation of mesothelioma.
  • The malignant potential of the tumor was estimated through histologic assessment of the degree of cellularity, mitotic activity, and nuclear pleomorphism.
  • Ipsilateral pleural recurrence remote to the original tumor site occurred in 6 of these patients with malignant microscopic characteristics at a mean of 9 months after resection.
  • There have been no recurrences among the other 27 patients with benign histologic features, and 31 patients remain alive at a median follow-up of 34.5 months.
  • [MeSH-major] Neoplasm Recurrence, Local. Neoplasms, Fibrous Tissue / surgery. Pleura / surgery. Pleural Neoplasms / surgery

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16354315.001).
  • [ISSN] 1525-7304
  • [Journal-full-title] Clinical lung cancer
  • [ISO-abbreviation] Clin Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


81. Rakha EA, Patil S, Abdulla K, Abdulkader M, Chaudry Z, Soomro IN: The sensitivity of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma. Diagn Cytopathol; 2010 Dec;38(12):874-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The sensitivity of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma.
  • Pleural malignant mesothelioma (MM), which is an aggressive neoplasm with a high mortality, frequently manifests initially as pleural effusions.
  • The sensitivity of cytologic examination for its diagnosis varies widely in literature and most of the figures are from earlier studies with conventional cytologic preparations.
  • The objective of this study was to provide the current evidence on the role and sensitivity of cytologic examination of pleural fluid in the diagnosis of MM.
  • We reviewed the cytologic findings in pleural effusions of a large series of histologically proven MM (234 cases) diagnosed in our institution between 2001 and 2008.
  • A specific diagnosis of MM was rendered or suspected in 53% (79 patients).
  • On review of the cytology slides, only four cases were upgraded from benign to suspicious compared to four cases downgraded from suspicious to atypical but no significant improvement to the diagnosis could be made on revision.
  • These data suggested that a cytologic diagnosis contributed useful information in patients with epithelioid and biphasic pleural MM.
  • [MeSH-major] Cytodiagnosis / methods. Mesothelioma / diagnosis. Mesothelioma / pathology. Pleural Effusion, Malignant / diagnosis. Pleural Effusion, Malignant / pathology. Pleural Neoplasms / diagnosis. Pleural Neoplasms / pathology

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Wiley-Liss, Inc.
  • (PMID = 20049969.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


82. Hayakawa M: [Pleural lipoma: report of a case]. Kyobu Geka; 2005 Dec;58(13):1185-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pleural lipoma: report of a case].
  • Although lipomas are the most common form of the benign neoplasm, occurrence within the thoracic cage is uncommon, and lipomas originating from the pleura are very rare.
  • A chest wall tumor was suspected based on the findings of computed tomography (CT) of the thorax.
  • The tumor was resected by video-assisted thoracoscopic surgery and the patient remains well with no recurrence 4 years postoperatively.
  • The resected tumor was a yellowish pleural mass and the pathological diagnosis was a benign lipoma.
  • It is possible to make a diagnosis of lipoma preoperatively by CT and magnetic resonance imaging (MRI), however, the correct differential diagnosis of lipoma and liposarcoma is imperfect only by radiological findings necessitating surgical removal if possible.
  • [MeSH-major] Lipoma / surgery. Pleural Neoplasms / surgery. Thoracic Surgery, Video-Assisted

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16359024.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


83. Kotoulas C, Fotinou M, Tsaroucha E, Konstantinou M, Lioulias A: Images in cardiothoracic surgery. Localized fibrous mesothelioma: an extremely rare benign pleural tumor. Ann Thorac Surg; 2006 Jun;81(6):2316
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Images in cardiothoracic surgery. Localized fibrous mesothelioma: an extremely rare benign pleural tumor.
  • [MeSH-major] Mesothelioma / radiography. Pleural Neoplasms / radiography. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16731187.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


84. Liu CC, Wang HW, Li FY, Hsu PK, Huang MH, Hsu WH, Hsu HS, Wang LS: Solitary fibrous tumors of the pleura: clinicopathological characteristics, immunohistochemical profiles, and surgical outcomes with long-term follow-up. Thorac Cardiovasc Surg; 2008 Aug;56(5):291-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary fibrous tumors of the pleura: clinicopathological characteristics, immunohistochemical profiles, and surgical outcomes with long-term follow-up.
  • BACKGROUND: Solitary fibrous tumors of the pleura (SFTP) are rare.
  • (2) to determine whether an immunohistochemical (IHC) study can be helpful in distinguishing benign from malignant SFTPs; and (3) to provide more complete information to better predict prognosis.
  • All cytologic studies of pleural effusion were negative for malignant cells.
  • Complete pleural resection with adequate safe margins was performed for all patients.
  • Eleven cases proved to have benign tumors and 4 had malignancies.
  • Conventional factors, including tumor size, tumor shape, symptomatic presentation, and histological type did not affect prognosis.
  • Interestingly, p16 expression was significantly associated with tumor recurrence ( P = 0.009).
  • CONCLUSION: Complete pleural resection with adequate safe margins can achieve satisfactory outcomes in a majority of cases, but long-term follow-up for all patients is recommended due to the potential for late tumor recurrence.
  • However, IHC studies of the CD-34 and bcl-2 biomarkers can be important for further differential diagnosis, and p16 expression can be used to predict tumor recurrence.
  • [MeSH-major] Biomarkers, Tumor / analysis. Immunohistochemistry. Pulmonary Surgical Procedures. Solitary Fibrous Tumor, Pleural
  • [MeSH-minor] Aged. Diagnosis, Differential. Disease-Free Survival. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local. Retrospective Studies. Time Factors. Treatment Outcome

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18615377.001).
  • [ISSN] 0171-6425
  • [Journal-full-title] The Thoracic and cardiovascular surgeon
  • [ISO-abbreviation] Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


85. Mohamed F, Vincent N, Cottier M, Peoc'h M, Merrouche Y, Patouillard B, Paul S, Genin C: Improvement of malignant serous effusions diagnosis by quantitative analysis of molecular claudin 4 expression. Biomarkers; 2010 Jun;15(4):315-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improvement of malignant serous effusions diagnosis by quantitative analysis of molecular claudin 4 expression.
  • Our aim was to improve the cytology diagnosis of malignancy in serous fluids with the quantification of claudins compared with various classic molecular markers using real-time reverse transcriptase-polymerase chain reaction (RT-PCR) method.
  • Peritoneal or pleural effusions of 56 patients were assessed as malignant from histological analysis and 19 as benign.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Membrane Proteins / metabolism. Neoplasms / diagnosis. Pleural Effusion, Malignant / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, Neoplasm / genetics. Antigens, Neoplasm / metabolism. Ascitic Fluid / metabolism. Cell Adhesion Molecules / genetics. Cell Adhesion Molecules / metabolism. Claudin-1. Claudin-4. Claudins. Female. Humans. Keratin-19 / genetics. Keratin-19 / metabolism. Keratin-20 / genetics. Keratin-20 / metabolism. Male. Middle Aged. Mucin-1 / genetics. Mucin-1 / metabolism. Mucins / genetics. Mucins / metabolism. Receptors, Cell Surface / genetics. Receptors, Cell Surface / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20175704.001).
  • [ISSN] 1366-5804
  • [Journal-full-title] Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals
  • [ISO-abbreviation] Biomarkers
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / CLDN1 protein, human; 0 / CLDN18 protein, human; 0 / CLDN4 protein, human; 0 / Cell Adhesion Molecules; 0 / Claudin-1; 0 / Claudin-4; 0 / Claudins; 0 / EPCAM protein, human; 0 / Keratin-19; 0 / Keratin-20; 0 / MUC19 protein, human; 0 / Membrane Proteins; 0 / Mucin-1; 0 / Mucins; 0 / Receptors, Cell Surface; 0 / carcinoembryonic antigen binding protein, human
  •  go-up   go-down


86. Savic S, Franco N, Grilli B, Barascud Ade V, Herzog M, Bode B, Loosli H, Spieler P, Schönegg R, Zlobec I, Clark DP, Herman JG, Bubendorf L: Fluorescence in situ hybridization in the definitive diagnosis of malignant mesothelioma in effusion cytology. Chest; 2010 Jul;138(1):137-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fluorescence in situ hybridization in the definitive diagnosis of malignant mesothelioma in effusion cytology.
  • The aim of our study was to test chromosomal aberrations detected by fluorescence in situ hybridization (FISH) in the diagnosis of MM in effusion cytology and to explore the potential role of p16, p14, and p15 gene methylation as an alternative mechanism of tumor suppressor gene inactivation.
  • METHODS: Fifty-two effusions of biopsy-proven MM and 28 benign effusions were retrospectively analyzed by multitarget FISH assay for aberrations of chromosomes 3, 7, 17, and 9p21.
  • All benign effusions were FISH negative.
  • Four of five FISH-negative biopsy specimens showed promoter methylation in p16 and p14 as compared with one of 12 benign controls.
  • CONCLUSIONS: FISH is a sensitive and highly specific method for the definitive diagnosis of MM in effusion cytology.
  • In the subset of FISH-negative MM, tumor suppressor genes on the chromosomal region 9p21 are often inactivated by promoter methylation.
  • [MeSH-major] In Situ Hybridization, Fluorescence / methods. Mesothelioma / pathology. Pleural Effusion, Malignant / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy. DNA, Neoplasm / analysis. Diagnosis, Differential. Female. Genes, p16. Humans. Male. Middle Aged. Pleural Effusion / diagnosis. Polymerase Chain Reaction. Retrospective Studies

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20139227.001).
  • [ISSN] 1931-3543
  • [Journal-full-title] Chest
  • [ISO-abbreviation] Chest
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


87. Huang WW, Tsao SM, Lai CL, Su CC, Tseng CE: Diagnostic value of Her-2/neu, Cyfra 21-1, and carcinoembryonic antigen levels in malignant pleural effusions of lung adenocarcinoma. Pathology; 2010 Apr;42(3):224-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic value of Her-2/neu, Cyfra 21-1, and carcinoembryonic antigen levels in malignant pleural effusions of lung adenocarcinoma.
  • AIMS: Cytology fails to detect neoplastic cells in 40-50% of cases of malignant pleural effusion, a condition that frequently accompanies lung adenocarcinoma.
  • Published reports of diagnostic sensitivity of various tumour markers are inconsistent, and optimal cut-off points have not been determined.
  • This study aimed to evaluate the ability of three markers to discriminate lung adenocarcinoma-associated malignant pleural effusion (LAC-MPE) from benign effusion.
  • METHODS: Pleural effusion samples were collected from 41 patients with LAC-MPE, and from 93 with various benign conditions.
  • RESULTS: Her-2/neu, Cyfra 21-1, and CEA vary in their diagnostic accuracy to differentiate LAC-MPE from benign pleural effusion: 79.85%, 88.81%, and 94.03%, respectively.
  • The results of the present study may help clinicians decide whether to obtain a cytological/histological specimen by invasive means to investigate a possible diagnosis of malignancy.
  • [MeSH-major] Adenocarcinoma / diagnosis. Antigens, Neoplasm / analysis. Carcinoembryonic Antigen / analysis. Keratin-19 / analysis. Lung Neoplasms / diagnosis. Pleural Effusion / metabolism. Receptor, ErbB-2 / analysis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Enzyme-Linked Immunosorbent Assay. Female. Humans. Male. Middle Aged. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20350214.001).
  • [ISSN] 1465-3931
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 0 / Keratin-19; 0 / antigen CYFRA21.1; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


88. Murthy SC, Rozas MS, Adelstein DJ, Mason DP, Calhoun R, Rybicki LA, Feng J, Blackstone EH, Rice TW: Induction chemoradiotherapy increases pleural and pericardial complications after esophagectomy for cancer. J Thorac Oncol; 2009 Mar;4(3):395-403
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction chemoradiotherapy increases pleural and pericardial complications after esophagectomy for cancer.
  • This study focuses on postesophagectomy benign pleural and pericardial complications to determine their prevalence, temporal pattern, and treatment, and their association with induction chemoradiotherapy and influence on survival.
  • Among these, occurrence of pleural effusion, pericardial effusion, and pericarditis was ascertained by follow-up.
  • RESULTS: During follow-up, 61 induction chemoradiotherapy patients experienced at least one pleural or pericardial complication, as did 46 propensity-matched surgery-only patients.
  • Risk of pleural effusion was nearly twice as great (hazard ratio 1.7, p = 0.0004) and pericardial complications 5 times greater (hazard ratio 5.3, p = 0.0005) after induction chemoradiotherapy than after surgery alone.
  • CONCLUSIONS: Benign pleural and pericardial complications occur surprisingly frequently after esophagectomy, particularly when induction chemoradiotherapy is employed.
  • [MeSH-major] Adenocarcinoma / therapy. Esophageal Neoplasms / therapy. Pericarditis / etiology. Pleural Effusion / etiology
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant / adverse effects. Cohort Studies. Esophagectomy / methods. Female. Humans. Incidence. Male. Middle Aged. Neoplasm Staging. Postoperative Complications / diagnosis. Postoperative Complications / epidemiology. Preoperative Care / methods. Probability. Radiotherapy, Adjuvant / adverse effects. Reference Values. Remission Induction. Retrospective Studies. Risk Assessment. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Pericardial Disorders.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Thorac Oncol. 2009 Mar;4(3):277-8 [19247080.001]
  • (PMID = 19247086.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


89. Wang T, Qian X, Wang Z, Wang L, Yu L, Ding Y, Liu B: Detection of cell-free BIRC5 mRNA in effusions and its potential diagnostic value for differentiating malignant and benign effusions. Int J Cancer; 2009 Oct 15;125(8):1921-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of cell-free BIRC5 mRNA in effusions and its potential diagnostic value for differentiating malignant and benign effusions.
  • The detection of circulating nucleic acids has long been explored for the diagnosis of a variety of clinical conditions.
  • Pleural fluids and ascites samples were collected prospectively from 112 patients.
  • Effusions were classified as benign or malignant on the basis of their definitive pathologic or cytologic diagnoses.
  • The expression of cell-free BIRC5 mRNA was statistically significantly higher in the malignant group than in the benign group.
  • Determination of BIRC5 and CEA in effusions could enhance diagnostic value in the diagnosis of malignant effusions.
  • [MeSH-major] Ascites / diagnosis. Cell Differentiation. Microtubule-Associated Proteins / genetics. Neoplasms / diagnosis. Pleural Effusion, Malignant / diagnosis. RNA, Messenger / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoembryonic Antigen / genetics. Carcinoembryonic Antigen / metabolism. Female. Humans. Inhibitor of Apoptosis Proteins. Male. Middle Aged. Neoplasm Staging. Prognosis. Prospective Studies. ROC Curve. Reverse Transcriptase Polymerase Chain Reaction. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19585499.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Carcinoembryonic Antigen; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / RNA, Messenger
  •  go-up   go-down


90. Chatti K, Nouira K, Ben Reguigua M, Bedioui H, Oueslati S, Laabidi B, Alaya M, Ben Abdallah N: [Solitary fibrous tumor of the pancreas. A case report]. Gastroenterol Clin Biol; 2006 Feb;30(2):317-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Solitary fibrous tumor of the pancreas. A case report].
  • [Transliterated title] Tumeur fibreuse solitaire du pancréas. A propos d'un cas.
  • Solitary fibrous tumour (SFT), a rare mesenchymal neoplasm usually arising from the pleura, may also occur in many other extra pleural sites.
  • This report describes the case of a benign SFT of the pancreas occurring in a 41-year-old man who presented with a solid epigastric mass.
  • Surgical resection of the tumour was performed, and the patient died from postoperative complications.
  • [MeSH-major] Neoplasms, Fibrous Tissue / diagnosis. Pancreatic Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16565671.001).
  • [ISSN] 0399-8320
  • [Journal-full-title] Gastroentérologie clinique et biologique
  • [ISO-abbreviation] Gastroenterol. Clin. Biol.
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


91. Terry NE, Fowler CL: Benign cystic mesothelioma in a child. J Pediatr Surg; 2009 May;44(5):e9-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign cystic mesothelioma in a child.
  • Grossly, it resembled lymphangioma; however, histopathologic diagnosis was benign cystic mesothelioma (BCM), an entity that presents mainly in women of childbearing age.
  • [MeSH-major] Mesothelioma, Cystic / diagnosis. Peritoneal Neoplasms / diagnosis
  • [MeSH-minor] Ascites / etiology. Cystic Adenomatoid Malformation of Lung, Congenital / complications. Cystic Adenomatoid Malformation of Lung, Congenital / surgery. Diagnosis, Differential. Dyspnea / etiology. Humans. Infant. Lymphangioma / diagnosis. Male. Neoplasm Recurrence, Local / surgery. Pleural Effusion / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19433159.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


92. Li H, Fu J, Xiu Y, Zhou Q: [Diagnostic significance of combining telomerase activity with CYFRA21-1 level in differentiating malignant pleural effusion caused by lung cancer from benign pleural effusion]. Zhongguo Fei Ai Za Zhi; 2010 Jun;13(6):652-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnostic significance of combining telomerase activity with CYFRA21-1 level in differentiating malignant pleural effusion caused by lung cancer from benign pleural effusion].
  • BACKGROUND AND OBJECTIVE Telomerase and CYFRA21-1 may be positively expressed in malignant pleural effusion, but the sensitivity and specificity of single tumor marker were low.
  • The aim of this study is to investigate the diagnostic value of combining determination of telomerase activity and CYFRA21-1 levels in differentiating benign from malignant pleural effusion caused by lung cancer.
  • METHODS: 80 patients with malignant and 50 patients with benign pleural effusion were enrolled into this study.
  • The telomerase activity in pleural effusion was tested by means of telomeric repeat amplification protocal-PCR-ELISA (TRAP-PCR-ELISA) and CYFRA21-1 levels were tested by the EIA method.
  • RESULTS: The levels of telomerase and CYFRA21-1 in malignant pleural effusion was significantly higher than that in benign one (t = 17.252 and t = 13.951, P < 0.001).
  • The sensitivity of telomerase activity testing for diagnosing malignant pleural effusion was 71.3%; the specificity was 86.0% and the overall accuracy was 76.9%.
  • CONCLUSION: The combined testing oftelomerase with CYFRA21-1 can increase the sensitivity and overall accuracy of differential diagnosis of benign and malignant pleural effusion diagnosis.
  • [MeSH-major] Antigens, Neoplasm / analysis. Keratin-19 / analysis. Pleural Effusion / diagnosis. Pleural Effusion, Malignant / diagnosis. Telomerase / metabolism
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20681457.001).
  • [ISSN] 1009-3419
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Keratin-19; 0 / antigen CYFRA21.1; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


93. Li W, Ni Y, Tu Z, Wu S, Wu Z, Zheng S: Study of telomerase activity in pleural lavage fluid specimens in patients with non-small-cell lung cancer and its clinical significance. Eur J Cardiothorac Surg; 2009 Sep;36(3):460-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Study of telomerase activity in pleural lavage fluid specimens in patients with non-small-cell lung cancer and its clinical significance.
  • OBJECTIVE: To detect telomerase activity in pleural lavage fluid specimens in patients with non-small-cell lung cancer (NSCLC) and to evaluate its clinical value.
  • METHODS: From July 2005 to May 2007, 167 pleural lavage fluid specimens were obtained from 135 patients with NSCLC and 32 patients with benign lung tumour during operation.
  • Pleural lavage cytology (PLC) analysis of the pleural lavage fluid specimens was used for comparison.
  • RESULTS: The positive rate of telomerase activity and PLC in pleural lavage fluid from patients with NSCLC was 25.2% (34/135) and 8.1% (11/135), respectively, with a significant difference (P<0.05).
  • Telomerase activity was negative in all 32 patients with benign lung tumour.
  • There was a significant relationship between telomerase activity and pleural extension, T level, N level as well as the clinical TNM (tumour, node, metastasis) stage of lung cancer.
  • CONCLUSION: Telomerase activity is a useful adjunct for cytological method in the diagnosis of pleural micro-metastasis and was related to prognosis in a patient with NSCLC.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma, Non-Small-Cell Lung / enzymology. Lung Neoplasms / enzymology. Pleural Cavity / enzymology. Pleural Neoplasms / secondary. Telomerase / metabolism
  • [MeSH-minor] Adult. Aged. Clinical Enzyme Tests / methods. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Survival Analysis. Therapeutic Irrigation

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19502078.001).
  • [ISSN] 1873-734X
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


94. Szczepulska-Wójcik E, Langfort R, Roszkowski-Sliz K: [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation]. Pneumonol Alergol Pol; 2007;75(1):57-69
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation].
  • INTRODUCTION: Histopathological diagnosis of malignant mesothelioma (MM) and differentiating it from tumors infiltrating the pleura is very difficult.
  • Distinguishing benign reactive mesothelial cell proliferation from MM also presents problems.
  • The objective of this study was to evaluate the significance of selected immunohistochemical stains in differentiating MM from non-small cell lung cancers infiltrating the pleura and from benign reactive mesothelial cell proliferation.
  • MATERIAL AND METHODS: The material encompassed 86 cases of MM, 54 cases of NSCLC infiltrating the pleura, and 43 cases of benign reactive mesothelial cell proliferation.
  • Non-small cell lung cancers infiltrating the pleura: Coexpression of cytokeratin and vimentin was found in 17.6% of the cases, positive staining of membranes for EMA, in 13% cases.
  • Benign reactive mesothelial cell proliferation: Protein p53 was present in 9.3% of cases, whereas no positive staining for EMA was found.
  • In the diagnosis of spindle-cell pleural tumors and the fibrous form of MM and benign reactive mesothelial cell proliferation , markers of mesothelial cells are noncontributory.
  • Immunohistochemical staining fails to identify a reactive process, but a diffuse, positive stain for EMA and the presence of protein p53 support the diagnosis of MM.
  • [MeSH-major] Antigens, Tumor-Associated, Carbohydrate / analysis. Biomarkers, Tumor / analysis. Carcinoma, Non-Small-Cell Lung / pathology. Mesothelioma / pathology. Neoplasm Proteins / analysis. Neoplasms, Mesothelial / pathology. Pleural Neoplasms / pathology
  • [MeSH-minor] Aged. Antibodies, Monoclonal / analysis. Diagnosis, Differential. Epithelium / chemistry. Epithelium / pathology. Female. Humans. Hyperplasia / pathology. Immunohistochemistry. Lung / chemistry. Lung / pathology. Male. Middle Aged. Pleura / chemistry. Pleura / pathology. Pleural Effusion / chemistry. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17541913.001).
  • [ISSN] 0867-7077
  • [Journal-full-title] Pneumonologia i alergologia polska
  • [ISO-abbreviation] Pneumonol Alergol Pol
  • [Language] pol
  • [Publication-type] Comparative Study; English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, Tumor-Associated, Carbohydrate; 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  •  go-up   go-down


95. Kumasaka T, Seyama K, Mitani K, Souma S, Kashiwagi S, Hebisawa A, Sato T, Kubo H, Gomi K, Shibuya K, Fukuchi Y, Suda K: Lymphangiogenesis-mediated shedding of LAM cell clusters as a mechanism for dissemination in lymphangioleiomyomatosis. Am J Surg Pathol; 2005 Oct;29(10):1356-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recent studies indicate that LAM cells can migrate or metastasize to form new lesions in multiple organs, although they show a morphologically benign appearance.
  • In this study, we further focused on the lymphatic abnormalities in LAM: LAM-associated chylous fluid (5 pleural effusion and 2 ascites), surgically resected diaphragm (1 patient), and axial lymphatic system including the thoracic duct, lymph nodes at various regions, and diaphragmatic lymphatic system (5 autopsy cases).
  • [MeSH-major] Endothelial Cells / pathology. Lymphangiogenesis. Lymphangioleiomyomatosis / pathology. Neoplasm Metastasis / pathology. Neoplastic Cells, Circulating / pathology


96. Economidou F, Tzortzaki EG, Schiza S, Antoniou KM, Neofytou E, Zervou M, Lambiri I, Siafakas NM: Microsatellite DNA analysis does not distinguish malignant from benign pleural effusions. Oncol Rep; 2007 Dec;18(6):1507-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microsatellite DNA analysis does not distinguish malignant from benign pleural effusions.
  • Distinguishing malignant from benign pleural effusions using routine cytology is a common diagnostic problem.
  • Recently, genetic alterations, including microsatellite instability (MSI) and loss of heterozygosity (LOH), have been described in malignant pleural effusions and proposed as methods improving diagnostics.
  • The purpose of this study was to evaluate a panel of molecular markers for the detection of genetic alterations of cells in pleural effusions and to determine their diagnostic value as an additional test to cytologic examination.
  • Pleural fluid and peripheral blood from 48 patients (36 male and 12 female, median age 71 years) were analyzed.
  • Twenty-six patients had malignant pleural effusion, including 23 lung cancer and three metastatic non-pulmonary carcinoma.
  • The control group consisted of 22 patients with benign pleural effusions.
  • Only 14 malignancy-associated pleural effusions were cytology-positive for malignant cells (54%), whereas all benign pleural effusions were negative.
  • Microsatellite analysis of the pleural fluid pellet exhibited genetic alterations in two neoplastic pleural fluid cases and in one inflammatory case.
  • Two out of 26 (7.6%) patients with malignant pleural effusion showed genetic alterations.
  • One out of 22 (4.5%) patients with benign pleural effusion showed LOH in marker D3S134.
  • In conclusion, genetic alterations at the level of microsatellite DNA, were detected only in very few cases of malignant pleural effusions, and in one case of benign pleural effusion.
  • Thus, our data suggest that microsatellite DNA analysis does not facilitate the diagnosis of malignant pleural effusion.
  • [MeSH-major] DNA / genetics. DNA, Neoplasm / genetics. Microsatellite Repeats. Pleural Effusion / physiopathology. Pleural Neoplasms / physiopathology
  • [MeSH-minor] Aged. Aged, 80 and over. Chromosome Mapping. Chromosomes, Human. Female. Genomic Instability. Humans. L-Lactate Dehydrogenase / analysis. Male. Middle Aged. Neoplasm Proteins / analysis. Proteins / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17982637.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Neoplasm Proteins; 0 / Proteins; 9007-49-2 / DNA; EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


97. Afify AM, Stern R, Michael CW: Differentiation of mesothelioma from adenocarcinoma in serous effusions: the role of hyaluronic acid and CD44 localization. Diagn Cytopathol; 2005 Mar;32(3):145-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All MMs and 93% (26/28) of the benign mesothelial cells were positive for intracytoplasmic HA vs. none of ACAs.
  • CD44 may prove useful in conjunction with other stains in the differential diagnosis of mesothelioma and ADA.
  • [MeSH-major] Adenocarcinoma / diagnosis. Antigens, CD44 / metabolism. Ascitic Fluid / metabolism. Hyaluronic Acid / metabolism. Mesothelioma / diagnosis. Pleural Effusion, Malignant / metabolism
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Neoplasm Metastasis. Staining and Labeling

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. HYALURONIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc.
  • (PMID = 15690337.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Biomarkers, Tumor; 0 / CD44S antigen; 9004-61-9 / Hyaluronic Acid
  •  go-up   go-down


98. Alberti N, Serrano-Egea A, García-García E, Ballestín C, Pérez-Barrios A, López-Ríos F, de Agustín P: Primary papillary serous carcinoma of the peritoneum: report of a case with diagnosis by fine needle aspiration and immunocytochemistry. Acta Cytol; 2007 Mar-Apr;51(2):203-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary papillary serous carcinoma of the peritoneum: report of a case with diagnosis by fine needle aspiration and immunocytochemistry.
  • BACKGROUND: Primary papillary serous carcinoma (PPSC) of the peritoneum is a rare neoplasm, histologically indistinguishable from papillary serous carcinoma of the ovary, which diffusely involves the peritoneum but spares or minimally invades the ovaries.
  • To the best of our knowledge, the preoperative and the fine needle aspiration diagnosis of this disorder have not been reported before.
  • CASE: A woman developed an extensive peritoneal neoplasm 4 years after hysterectomy and bilateral salpingo-oophorectomy for benign disease.
  • Fine needle aspiration of the tumor was performed, and the cytologic and immunocytochemical findings were consistent with papillary serous carcinoma.
  • A diagnosis of PPSC of the peritoneum was rendered because review of all slides from previous surgical specimens showed no evidence of carcinoma and no other primary tumors were found elsewhere.
  • CONCLUSION: Fine needle aspiration cytology coupled with immunocytochemical and clinical data allows an unequivocal preoperative diagnosis of papillary serous carcinoma (primary peritoneal or with an ovarian origin).
  • Based on this fact, the preoperative fine needle aspiration cytology diagnosis of PSCP should be restricted to oophorectomized patients.
  • [MeSH-major] Cystadenocarcinoma, Papillary / diagnosis. Cystadenocarcinoma, Serous / diagnosis. Ovarian Neoplasms / diagnosis. Peritoneal Neoplasms / diagnosis
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ascites / etiology. Biomarkers, Tumor / analysis. Biomarkers, Tumor / biosynthesis. Biopsy, Fine-Needle / methods. Diagnosis, Differential. Female. Humans. Hysterectomy. Immunohistochemistry / methods. Middle Aged. Pleural Effusion, Malignant / etiology. Pleural Effusion, Malignant / pathology. Predictive Value of Tests. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17425204.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


99. Upile T, Triaridis S, Kirkland P, Goldstraw P, Rhys Evans P: How we do it: the anterior thoraco-cervical approach to tumours of the thoracic inlet. Clin Otolaryngol; 2005 Dec;30(6):561-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • KEYPOINTS: Tumours that arise in the thoracic inlet and superior mediastinum may be benign or malignant and present the surgeon with a difficult problem of access.
  • The approach offers excellent exposure and helps to facilitate complete resection of benign and malignant tumours, which would otherwise be deemed inoperable or difficult to resect completely through other standard approaches.
  • [MeSH-minor] Chylothorax / etiology. Dissection. Follow-Up Studies. Humans. Mediastinal Neoplasms / surgery. Mediastinum / surgery. Neck Muscles / surgery. Neoplasm Metastasis. Neoplasm Recurrence, Local / surgery. Pleural Effusion / etiology. Postoperative Complications. Postoperative Hemorrhage / etiology. Sternum / surgery. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16402986.001).
  • [ISSN] 1749-4478
  • [Journal-full-title] Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery
  • [ISO-abbreviation] Clin Otolaryngol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


100. Zendehrokh N, Rehnberg J, Dejmek A: Comparison of NCL-hTERT antibody reactivity and telomere repeat amplification protocol in situ in effusions. Acta Cytol; 2007 Nov-Dec;51(6):886-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The results were compared and correlated to diagnosis.
  • Twenty effusions, all containing mesothelial cells, came from patients with benign conditions.
  • Thus the results of TRAP in situ and hTERT immunohistochemistry disagreed in 1 of 34 (3%) malignant and 12 of 20 (60%) benign cases.
  • [MeSH-major] Ascitic Fluid / enzymology. Immunohistochemistry / methods. Pleural Effusion / enzymology. Polymerase Chain Reaction / methods. Telomerase / metabolism. Telomere / enzymology
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Cell Nucleus / enzymology. Cell Nucleus / genetics. DNA, Neoplasm / analysis. Female. Humans. Neoplasms, Mesothelial / diagnosis. Neoplasms, Mesothelial / enzymology. Phosphoproteins / immunology. Phosphoproteins / metabolism. RNA-Binding Proteins / immunology. RNA-Binding Proteins / metabolism. Repetitive Sequences, Nucleic Acid / genetics. Reproducibility of Results. Sensitivity and Specificity

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18077981.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / Phosphoproteins; 0 / RNA-Binding Proteins; 0 / nucleolin; EC 2.7.7.49 / TERT protein, human; EC 2.7.7.49 / Telomerase
  •  go-up   go-down






Advertisement